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CHAPTER I 
INTRODUCTION 
Anthracyclines, such as daunomycin and adriamycin have been the 
subject of intense recent investigation. Many of these studies have 
been, partially at least, motivated by the demonstrated effectiveness 
of anthracyclines in the treatment of leukemias and other forms of 
cancer. 
The biological and pharmacological activities of these drugs 
appear to be, at least in part, due to their ability to interact with 
DNA. Specifically, daunomycin and adriamycin can intercalate into DNA 
and inactivate its template function essential for nucleic acid synthe-
sis. 
Recently, several structural analogs of these antineoplastic 
agents have been synthesized and some of them were shown to be consider-
ably more effective against experimental tumors than the parent compounds. 
The majority of recent studies of these daunomycin derivatives have indi-
cated that the increased effectiveness of these new drugs may relate to 
their different modes of interaction with the target molecule, DNA. 
Clearly the interaction between anthracyclines and the DNA 
template may be expected to influence the mechanism by which these anti-
biotics inhibit nucleic acid synthesis. However, very little information 
is available in this area. The goal of this research project is to study 
the mechanism by which several structurally related anthracyclines in-
hibit the synthesis of RNA. 
1 
2 
r.l. Structures of Anthracycline Analogs: 
Daunomycin (daunorubicin) is an antibiotic isolated from cul-
tures of streptomyces peucetius (DiMarco et al., l964a). This drug in-
hibits strongly the multiplication of bacterial and animal viruses and 
exhibits a high cytotoxic activity against normal and neoplastic cells 
(DiMarco et al., 1964b). The active form of the drug was isolated as 
crystalline hydrochloride with the empirical formula: c27H29o10N•HC1. The 
structure of daunomycin has been shown to be a glycosidic antibiotic 
constituted by a red, water insoluble, tetracyclic aglycone (daunomy-
cinone, c21H18o8 ) (Arcamone, et al., 1964a) linked to a reducing (posi-
tive Fehling, Tollens tests), water soluble amino-sugar (positive Elson-
Morgan ninhydrin) named daunosamine or 2,3,6-trideoxy-3-amino-L-
lyxohexose (c6 H13No 3 ) (Arcamone et al., 1964b). Mild acid hydrolysis 
(0.2N hydrochloric acid for 1 hr. at 90°C) can resolve the drug into its 
two components (Arcamone et al., 1964). The structure and absolute con-
figuration of daunomycin and its components are now known in detail 
(Arcamone et al., 1968) and are presented in Figure la. 
From the X-ray crystallographic studies of the N-bromoacetyl 
derivative of daunomycin, the shape of the molecule in the solid state is 
shown in Figure 2. The cyclohexene ring or ring D is in the "half-chair" 
conformation (Angiuli et al., 1971) and the C-9 is displaced from the 
0 
plane of the remaining five atoms by about 7 A and toward the C-9 
hydroxyl. A more detailed picture can be found in Figure 4A. The six 
membered daunosamine ring was found to be in the chair conformation ori-
ented perpendicularly to the planar chromophore. 
The physico-chemical characteristics of daunomycin show remarkable 
Figure l. Structures of anthracycline analogs: 
(a) Daunomycin; 
(c) carminomycin; 
(e) marcellomycin; 
(b) 4-demethoxydaunomycin; 
(d) aclacinomycin; 
(f) musettamycin. 
3 
4 
(a) 
' 1 
ANTHRACYCLINES Rl R2 R3 R4 Rs R6 R7 RB 
a) DAUNOMYCIN H OCP.3 OH H 0 CH3 H (H)2 
b) 4-DEMETHOXYDAUNOMYCIN H H OH H 0 CH3 H (H)2 
c) CARMINOMYCIN H OH OH H 0 CH3 H (H) 2 
d) ACLACINOMYCIN H OH H COOCH3 H2 CH3 DF*-C** (CH ) 3 2 
e) MARCELLOMYCIN OH OH H COOCH3 H2 CH 3 DF*-DF* (CH ) 3 2 
f) MUSETTAMYCIN OH OH H COOCH3 H2 CH3 DF* (CH3) 2 
*DF: 2-DEOXYFUCOSE 
**C: CINERULOSE 
Figure 2. Three-dimensional structure of N-bromoacetyldaunomycin 
as indicated by X-ray analysis 
6 
7 
8 
similarities with those of the antibiotics classified as "Anthracyclines" 
(Ollis et at., 1961) and therefore it is accepted as a member of the 
anthracycline family (Zunino et al., 1972). 
Adriamycin (14-hydroxydaunomycin) was obtained from cultures of 
streptomyces peucetius var. caesius (Arcamone et al., 1969a). This anti-
biotic gave, on acid hydrolysis, the aglycone, adriamycinone (14-
hydroxydaunomycinone), and the amino sugar daunosamine. The structure 
and absolute configuration of adriamycin were established on the basis of 
chemical and spectroscopic evidence (Arcamone et al., 1969b) and are also 
shown in Figure 1. 
The structures of the rest of the anthracycline analogs studied 
in this project are also shown in Figure 1 and they will be discussed 
separately in a latter section. 
I.2. Pharmacological and Biological Properties of Daunomycin and Its 
Analogs 
L 2 .1. Antibiotic Activity 
While only weakly active against some gram-positive and gram-
negative bacteria and fungi (DiMarco, 1967), daunomycin shows much 
higher inhibitory activity against the multiplication of other bacteria 
such as E. coli; although different strains of E. coli have different 
susceptibilities (DiMarco et al., 1975). 
Daunomycin was found to be active against the multiplication of 
double-stranded DNA bacteriophage (e.g. T6) but not single-stranded DNA 
bacteriophage (e.g. EC9 and 513) (Calendi et al., 1966). The interfe-
renee is not related to a direct inactivation of the phage particles or 
an inhibition of their absorption to the bacterial cell (Parisi et al., 
1964). 
The inhibitory effect of daunomycin was also demonstrated on 
other double-stranded DNA viruses (e.g. Herpes simplex virus) when ad-
ministered before or at the early stage of infection. It is not effec-
tive after mature virions appear (DiMarco et al., 1968). 
9 
Daunomycin is ineffective against the replication of animal RNA-
viruses with the exception of Newcastle Disease Virus (NDV) providing 
that the daunomycin-NOV mixtures are exposed to light (Verini et al., 
1968). 
By evaluation of the number of mitotic figures (mitotic index, 
MI) or of the proliferative activity of cells it was shown that daunomy-
cin has a strong inhibiting effect on the in vitro growth of a number 
10 
of cells strains both normal and neoplastic (DiMarco et al., 1975). 
cell damage induced by daunomycin is mainly nuclear, such as changes in 
the appearance of chromatin as well as the shape and size of the nucleoli. 
The changes appear soon after daunomycin addition to the medium of cell 
culture. During mitosis, chromosomal damage, such as fragmentations and 
mitotic aberrations can be observed by phase microscopy immediately after 
a sufficient amount of daunomycin is added (DiMarco et al., 1964b). 
Cytoplasmic changes, such as vacuolization, are moderate and occur only 
after prolonged treatment with high doses. Adriamycin also was found to 
induce significant alterations in membranes characterized by altered 
cellular agglutination ability and mitotic arrest (Murphree et at., 1976). 
Daunomycin also has a strong inhibitory effect on experimental 
tumor cells such as ascites tumor; solid tumors show a lesser susceptibi-
lity (DiMarco et al., 1970). Adriamycin is more effective than daunomy-
cin in increasing survival time in animals bearing Ehrlich ascites tumors 
(DiMarco et al., 1969) or Ll210 leukemia (Sandberg et al., 1970) and 
exerts a high inhibitory effect on the growth of many other experimental 
tumors (DiMarco et al., 1971). It is under these experimental conditions 
that the difference between the two antibiotics is particularly evident. 
I.2.2. Drug Distribution and Excretion 
With the advantage of the fluorescence property of the anthra-
cyclines, the distribution and excretion of daunomycin and adriamycin 
have been studied in animals (Di Fronzo and Gambetta, 197la; Di Fonzo 
et al., l97lb). Both drugs are rapidly cleared from the blood stream 
and fixed by body tissues and organs. The two antibiotics do not appear 
11 
to cross the blood brain barrier. 
As it is expected for drugs which interfere with nucleic acids 
synthesis (see section I.2.6.), the tissues most susceptible to the two 
antibiotics are rapidly proliferating such as intestinal mucosa, lymphoid 
organs and bone marrow (DiMarco et al., 1975). 
Both drugs are excreted slowly into urine and the bile, however, 
adriamycin was found to be excreted much slower than daunomycin in rats 
and mice (Yesair et al., 1971). The calculated "concentration x time" 
(C x t) in the case of adriamycin equivalents has been demonstrated in 
all tissues to be several times greater than that found for daunomycin. 
I. 2. 3. Drug Metabolism 
As indicated in the metabolic pathway depicted in Figure 3, 
daunomycin is metabolized by a aldo-keto reductase, daunomycin reductase 
(Bachur et al., 1971) to form daunorubicinol. This reduced product is 
not only the pricipal drug form excreted by human and animals (Cradock 
et al., 1973: Bachur et al., 1974) but also retains significant cytotoxic 
activity. 
Daunomycin and daunorubicinol can also be further metabolized 
by either reductive or hydrolytic glycosidases (Bachur et al., 1972) to 
form aglycones which have low water but high lipid solubility. Solubi-
lization of these aglycones can take place through 0-~-glucuronidation 
and 0-sulfation (Takanashi e~ al., 1975). The conjugate products can 
then be excreted through urine. 
I.2.4. Clinical Toxicity 
The most frequent signs of toxicity caused in patients by both 
Figure 3. Proposed pathway for human daunmycin metabolism 
I. daunomycin; II, daunorubicinol; III, daunorubicinol aglycone; 
IV, deoxydaunorubicin aglycone; V, deoxydaunorubicinol aglycone; 
VI, demethyl deoxydaunorubicinol aglycone; VII, deoxydaunorubicinol 
aglycone-13-0-~--glucuronide; VIII, demethyl deoxydaunorubicinol 
aglycone-4-0-sulfate; IX, demethyl deoxydaunorubicinol aglycone-4-0 
~-glucuronide. 
12 
CH 
0 :€Jf 
CH-CH3 
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daunomycin and adriamycin are stomatitis, alopecia, bone marrow depres-
sion, and gastrointestinal disturbances (Bernard et al., 1969). No sig-
nificant kidney damage has been reported. A peculiar toxic effect of 
these drugs is a cardiopulmonary syndrome (Bonadonna et al., 1969) con-
sisting of tachycardia, with or without arrhythmia, hypotension, gallop 
rhythm, tachypnea, and congestive heart failure, not relieved by digi-
talis. The mechanism of this effect has not been elucidated. Cardiac 
toxicity is more frequently observed when high doses (more than 25-30 
mg/kg) are given, and in elderly patients (DiMarco et al., 1975). When 
an intermittent, rather than a daily dose schedule is used, cardiac 
toxicity is rarely observed. 
I.2.5. Therapeutic Values 
The main therapeutic indications of daunomycin and adriamycin 
are leukemias, especially acute lymphocytic leukemia in children. Be-
cause of the occurence of cardiac toxicity, the drugs are used, alone or 
in combination with other antitumor agents, mainly for remission induction 
and reinforcement dosing during remissions rather than for maintenance 
therapy (DiMarco et al., 1975). Both daunomycin and adriamycin are also 
active on lymphomatous neoplasms (e.g. Hodgkin's disease lymphosarcoma, 
reticular cell sarcoma) . 
Daunomycin has little or no effect on solid tumors, whereas 
adriamycin appears to be temporarily effective in a range of childhood 
tumors such as Ewing's sarcoma, neublastoma, osteogenic sarcoma and some 
anaplastic sarcomas (Bonadonna et al., 1970). In adults, chemothera-
peutic effectiveness has been obtained in breast cancer, seminoma, ges-
15 
tional choricocaricinoma and other soft tissue sarcomas, transitional 
cell carcinomas of the bladder, and lung cancer. 
I.2.6. The Mode of Action of Daunomycin and Its Analogs 
The fluorescence of daunomycin enables the investigation of the 
events which occur after the cells are incubated with the drug. It has 
been shown that daunomycin penetrates the cell and fixes itself in the 
nuclear structure (Calendi et al., 1965). The radiochemical data have 
confirmed that a large portion of daunomycin which enters the cell is 
taken up by the nucleus (DiMarco et al., 1975). In synchronized 
cultured cells it has been shown that the up-take of the drug occurs 
through the regenerative cycle, and reaches its maximum during DNA 
replication (Silvestrini et al., 1970). 
In cultures of mammalian cells, daunomycin strongly inhibits 
adenine-s-c14 incorporation into RNA (Rusconi et al., 1966). This inter-
ference with the incorporation of labeled precursors into RNA is consis-
tent with the findings that daunomycin inhibits in vitro DNA-dependent 
RNA polymerase (DiMarco et al., 1965). In cultured animal cells, RNA 
synthesis in the nucleolus is particularly sensitive to the drug (Angiuli 
et al., 1971). Autoradiographic studies carried out in vitro cultures of 
Hela cells (DiMarco et al., 1965; Crook et al., 1972) showed a higher 
inhibition of ribosomal RNA synthesis than messenger RNA synthesis. This 
preferential inhibition of nucleolar RNA is described in more detail in 
section I.2.8.1. 
Inhibition of DNA synthesis by daunomycin has also been observed 
by following the incorporation of 3H-thymidine into nucleic acids 
16 
(Rusconi et al., 1969). This inhibitory effect of daunomycin is correla-
ted with the interference of daunomycin with the activity of DNA-dependent 
DNA polymerase (Hartman et al., 1964). 
Studies have shown that when the daunomycin and the precursors 
of nucleic acids synthesis are added to the cell cultures at the same 
time, there are no significant differences in the relative inhibition of 
precursors uptake into DNA or RNA (Rusconi et al., 1969). Other auto-
radiographic studies have reported the influence of daunomycin on nucleic 
acids synthesis during different phases of cell cycle (Silvestrini et 
al., 1970). The effect of daunomycin inhibition is more evident on DNA 
synthesis which occurs in the late S phase, tentatively indentified with 
heterochromatin duplication and on RNA synthesis which occurs in the 
middle of G1 and in the G2 phases just before the mitotic peak (Simard, 
1967). The observation (Kim et al., 1968) that the lethal effect of 
-- --
duanomycin on a synchronously dividing population of Hela cells is higher 
inS phase than in G1 or G2 phase suggeststhat the accessibility of DNA 
in chromosomal structures and repair processes may vary during the divi-
sian cycle. Since a strong binding of daunomycin to DNA occurs only with 
double-stranded DNA (see section I.2.7.2.), one might assume that during 
the process of replication the drug could find access to DNA, bind strong-
ly and irreversibly damage the chromosomal structure to cause cell death. 
In any event, the inhibition of these important metabolic events such as 
nucleic acid synthesis can explain the arrest of cullular reproduction. 
However, an immediate antimitotic activity of daunomycin (see section 
I.2.1.) which seems to be unrelated to the inhibition of RNA of DNA 
synthesis may indicate that the stiffening of DNA by the drug, which will 
17 
be discussed in the following section, may contribute to the chromosomal 
damage (Di Marco, 1967). 
I.2.7. The Mechanism of Action of Daunomycin 
Substantial amount of evidence suggest that daunomycin interferes 
with template activity by intercalating between the base pairs of the 
double helical DNA. 
I.2.7.l. Spectral Evidence for Drug Binding to DNA 
Initially, studies on the interaction of daunomycin with DNA 
(Calendi et al., 1965) revealed some physico-chemical changes upon for-
mation of the daunomycin-DNA complex. Daunomycin absorbs in the visible 
range with a maximum at 475 nm. Its ultraviolet absorption spectrum 
shows two maxima at 233 nm and 255 nm. Daunomycin also shows a typical 
fluorescence spectrum with an emission at 580 nm when exicted at 485 nm. 
When native or heat denatured DNA from various sources are added 
to an aqueous solution of daunomycin the antibiotic shows: (a) changes in 
visible absorption spectrum (both hypochromic, lowering of the absorbance 
at 475 nm, and bathochromic, shifting of its absorption maximum to 505 
nm); (b) changes in ultraviolet absorption spectrum (lowering of absor-
bance at 233 nm and 255 nm and shifting of the two absorption maxima to a 
single maximum at 257 nm); (c) reduction of antibiotic fluoresence (almost 
complete disappearance of fluorescence) (Calendi et al., 1965). No such 
changes are observed when nucleotides, nucleosides, or free based are 
added to daunomycin solution. 
Daunomycin aqueous solution is characterized by its red color. 
18 
At alkaline pH (9.4-9.8), the drug changes its color to blue due to salt 
formation of the compound (Calendi et al., 1965), and this color change 
can be prevented upon addition of DNA. 
These spectral changes of daunomycin upon addition of DNA indi-
cate that the drug binds to both native and denatured DNA. However, this 
binding is greatly reduced with derivatives of daunomycin where there is 
an alteration on amino sugar or complete removal of daunosamine, indica-
ting that the amino group of daunosamine is actively involved in the 
binding process. 
I.2.7.2. Evidence for Intercalation 
Upon binding to daunomycin, there are also many changes in the 
physico-chemical properties of double-stranded DNA. These changes in-
elude a) an increase in the intrinsic viscosity of DNA (Zunino, 1971), b) 
a decrease in the buoyant density of DNA (Kersten et al., 1966), c) a de-
crease of the sedimentation coefficient of DNA (Calendi et al., 1965; 
Kersten et al., 1966), d) a stabilization of DNA against thermal denatu-
ration, or in increase in the melting temperature of DNA (Zunino et al., 
1972) and e) a protection of DNA from degredation by nucleolytic enzymes 
(nucleases) (Zeleznick et al., 1967). 
According to Lerman's hypothesis on the interaction of 9-amino-
acridine with DNA, and increase in the intrinsic viscosity of DNA when 
bound to antibiotics is accepted as a diagnostic feature of an intercala-
tion process (DiMarco et al., 197lb). 
--
This phenomenon is attributed to 
a stiffening and elongation of the double-stranded DNA molecules when 
drugs are inserted into the hydrophobic areas between the flat base pairs 
19 
of the DNA helix (Evans et al., 1973). Besides, the planar aromatic ring 
system of daunomycin meets the requirement for the intercalation theory 
in which the drug must be "flat" to fit the space between by the base 
pairs (Gabby et al., 1976). The intrinsic viscosity of DNA is markedly 
less enhanced by all the derivatives of daunomycin with altered amino 
sugar than by other derivatives containing unsubstituted daunosamine 
(Calendi et al., 1965) indicating again that the amino group on daunosa-
mine contributes to strengthening the intercalative binding. 
In contrast to its effects on the native DNA, daunomycin causes 
a marked decrease in intrinsic viscosity of denatured DNA. This effect 
parallels the results reported for acridine dyes (Drummond et al., 1966). 
In the case of acridine dyes the effect of binding on the intrinsic vis-
cosity of denatured DNA is quantitatively the same as that achieved by 
adding neutral electrolyte and has usually been attributed to a decrease 
in mutual repulsion between the charged groups of a flexible polyelectro-
lyte chain (e.g. phosphate groups) of DNA. The effect of daunomycin 
binding on denatured DNA could be explained by the effects of the posi-
tively charged amino groups of daunosamine on the mutual repulsion of the 
phosphate groups, suggesting that daunomycin also, like acridines, binds 
in the non-helical regions of DNA as in the denatured state (Zunino et 
al., 1972). 
The decrease of the sedimentation coefficient of daunomycin.-bound 
double-stranded DNA is explained by the uncoiling of the helix at the 
point of drug insertion which alters the average pitch on the helix and 
causes an increase in the average number of base pairs per turn (Di Marco 
et al., l97lb). 
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The increase in the melting point (Tm) of DNA upon binding to 
daunomycin indicates that there is an interaction between daunomycin and 
DNA which stabilizes the association of the two strands (Calendi et al., 
1965). This increase in Tm is dependent upon the drug to DNA ratio 
(Zunino et al., 1972). Very little increase in Tm is observed for N-
acetyl daunomycin and other derivatives with substitution in the amino 
sugar moiety, again indicating that the amino group is actively involved 
in stablizing the intercalated complex. 
2+ Daunomycin can be removed from DNA by Mg and it can be extrac-
ted from aqueous solution of the complex by organic solvents such as 
phenol or n-butanol (DiMarco et al., 1972); at high ionic strengths, the 
binding of daunomycin to DNA is reduced (Bhuyan et al., 1965). Therefore, 
it seems that the complex formation involves electrostatic forces. 
Formamide, a hydrogen bond breaker, was found to revert com-
pletely the binding between N-acetyl derivatives and DNA and only par-
tially that between daunomycin and DNA (Calendi et al., 1965). This 
suggests that some of the bondings between the drug and DNA is of hydro-
gen bond type and the amino groups of the sugar moiety imparts to dauno-
mycin a much higher binding ability by providing greater possibility for 
hydrogen bonding. 
Other results correlate the structure of daunomycin and its de-
rivatives with their biological activities. It has been shown that when-
ever the amino hydrogen of daunosamine is not substituted and the CO 
group of the acetyl side chain on position C-9 is not altered, the com-
pounds are found to complex strongly to DNA and to inhibit mitotic acti-
vity, DNA synthesis and cell proliferation (Zunino et al., 1972). When 
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the CO group of the acetyl side chain is altered, the derivatives pre-
serve the ability to bind to DNA but with reduced antimitiotic activity 
and are inactive or slightly active in inhibiting DNA synthesis and 
cellular proliferation. It has been shown (Arcamone et al., l964b) that 
daunosamine, the amino sugar moiety of daunomycin, is an L-sugar, char-
acterized by L-lyxo conformation. When daunosamine is substituted with 
~-D-glucosamine or whenever the amino group is masked, the derivatives 
are found to bind to DNA very weakly and to lack biological activity 
(DiMarco et al., l97lb). This suggests the importance of the structure 
and of the stereochemistry of the amino sugar moiety in the binding 
reaction. 
All of these results have suggested two modes of binding between 
the antibiotic molecules and DNA: (l) the "strongly" bound antibiotic 
molecules are understood to be intercalated between successive base pairs 
of the double helix by the planar chromophore of the drug, facilitated by 
the positively charged amino sugar; (2) the "weakly" bound antibiotic 
molecules are thought to be attached to DNA by means of electrostatic 
interaction, involving the single-stranded DNA phosphate groups and, 
again, the daunosamine amino group. The shape of the isotherm (e.g. 
Figure 8) for the binding of daunomycin to DNA from spectrophotometric 
analysis (Zunino et al., 1972), the chromatographic behaviour of dauno-
mycin on DNA-cellulose column (Zunino, 1971) and.the X-ray-diffraction 
studies (Pigram et al., 1972) all support the intercalative model and 
the secondary binding of daunomycin to DNA. 
This intercalation theory can be used to explain the machanism 
of the inhibitory activity of daunomycin or bacterial and animal viruses 
22 
mentioned earlier. In fact, from the previously discusseddata, it seems 
that inhibition of the function or of the replication of the viral genome 
requires the formation of a strong association of the antibiotics with 
the nucleic acids, and, from physico-chemical studies, it is known that 
this strong binding of drug to DNA occurs only with double-helical DNA 
(Zunino et al., 1972). The lack of activity on single-stranded DNA 
(Calendi et al., 1966) or RNA (Cohen et al., 1969) viruses appears to be 
a direct consequence of the inability of the drug to form this stable 
binding. 
I.2.7.3. Models for Intercalation 
An initial intercalation model was proposed in which the amino 
sugar of daunomycin is in the major groove of the DNA (Pigram et al., 
1972). In this model the conformation of ring D of daunomycin was taken 
to be that found for the crystal structure of N-bromoacetyl daunomycin 
(Angiuli et al., 1971). In this structure C-9 is the most out of plane 
atom and the sugar is oriented axially with respect to ring D (Figure 4, 
conformation A). In this DNA-binding model, the daunomycin amino group 
binds to the second phosphate residue away from the intercalation site, 
and there is a hydrogen bond between the C-9 hydroxyl group and the first 
phosphate from the intercalation site (Goodman et al., 1977). A more 
recent analysis (Plumbridge et al., 1977) of the crystal structure of 
daunomycin however, suggests a slightly different preferred conformation 
of ring D (Figure 4, conformation B) in which C-8, rather than C-9, is 
the most out of plane atom and in which there is a hydrogen bond between 
the C-7 oxygen and C-9 hydroxyl group. The DNA-binding model, therefore, 
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Figure 4. The structure of daunomycin showing (a) the conformation 
of ring D for the crystal structure of N-bromoacetyldaunomycin, 
(b) that found for daunomycin, and (c) an alternative conformation 
for ring D. 
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needs to be revised to incorporated this intramolecular hydrogen bond. 
The conformation of ring D when the drug is bound to DNA may differ from 
the preferred conformation found in the crystal form. If the ring D 
conformation is altered so that C-8 lines behind rather than in front of 
the plane of the ring system as shown in Figure 4 then the amino sugar 
becomes oriented equatorially rather than axially (Figure 4, conformation 
c). Consequently there will be a spatially different interaction of the 
amino sugar in the major groove of the DNA (Pigram et al., 1972). The 
amino group will now bind to the first phosphate away from the interca-
lation site and there can be additional bonding in the form of hydrogen 
bonds between the C-4' hydroxyl group and the second phosphate from the 
site and between the C-9 hydroxyl and the phosphate at the intercalation 
site (there is no intramolecular hydrogen bond between the C-7 oxygen 
and the C-9 hydroxyl when the amino sugar is equatorial with respect to 
ring D). This latter model, therefore, provides for increased secondary 
stabilization of the intercalation complex. An inherent preference for 
daunomycin binding to A-T base pairs is also present (Plumbridge et al., 
1979). In all of these models, the C-14 hydroxyl group of adriamycin can 
additionally hydrogen bond with the DNA. This additional bond provides 
the basis for the higher potency of adriamycin as compared to daunomycin 
in their antitumor effects (DiMarco et al., 1969). 
Analogs of daunomycin have been used to test the validity of the 
main features and the fine details of these models (Brown, 1978; Arcamone, 
1977). However, these studies have not shown conclusively whether the 
analogs bind by the reinforced intercalation mechanism as shown in Figure 
4 conformation C. 
All of the models for daunomycin and DNA interactions suggests 
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that the binding will be more sensitive to changes in the sugar unit than 
in the C-9 substitutents. Consequently the effect of inversion of con-
figuration at C-7, C-1', C-3' and C-4' and the effect of deletion of C-4' 
hydroxyl group, on the mechanism of binding to DNA were studied (Arcamone 
et al., 1976; Zunino et al., 1977; DiMarco et at., 1977; Plumbridge et 
-- --
al., 1978). It was found that the reinforced intercalative binding to 
DNA which is typical of daunomycin can also occur if epimerization is 
present at C-4' or if the a-methyl group is lost or if the C-9 substitute 
is deleted or if the 4'-hydroxyl group is absent. In the latter two 
cases, however, there is a reduction in affinity for DNA, supporting the 
suggested role of the 9-hydroxyl and 4'-hydroxyl groups in the secondary 
stabilization of the complex. 
Epimerization at C-1' or at C-3' alters but does not abolish the 
intercalative mode of binding to DNA whereas epimerization at C-7 pre-
eludes intercalation of the chromophore into the helix of DNA (Plumbridge 
et al., 1979). All of these results tend to support the binding model in 
which ring D adopts conformation C in preference to the other binding 
models. 
In a separate report (Rich et al., 1981) a crystal of two dauno-
mycin molecules intercalating into a double helical DNA was obtained. The 
DNA contains two strands of a self-complementary hexanucleoside penta-
phosphate, d(CpGpTpApCdG). The saturation level for this intercalated 
complex is one daunomycin per three base pairs. 
X-ray diffraction studies revealed that the chromophore (rings 
A through D, Figure 5) intercalates into DNA with ring A protruding well 
into the major groove formed between base pairs Cl-G6* and G2-C5*. Ring 
Figure 5. Intermolecular attractions of intercalated daunomycin 
and d(CpGpTpApCpG) 
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D of the chrornophore and the attached amino sugar were found in the minor 
groove between base pairs G2-C5* and T3-A4*. Conformational changes for 
DNA molecules were also detected in this intercalated complex. Specifi-
0 
cally, base pairs are displaced by 1.3 A toward the major groove. An 8° 
unwinding of the DNA also takes place at the base pair one removed from 
the intercalation site. 
Tight hydrogen bonding are also formed in this intercalated corn-
plex. Figure 5 shows that the hydroxyl group on 09 forms a hydrogen bond 
with N3 of G2 by donating its hydrogen. This hydroxyl oxygen also re-
ceives a hydrogen from another amino group of G2. In the case of adria-
rnycin, the 14 hydroxyl group could form additional hydrogen bonding with 
03' of G2. These hydrogen bonds may provide "anchoring function" holding 
the antibiotic to the double helix. 
According to this data, ring D seems to adopt conformation A in 
Figure 4 which places the positively charged amino group in the minor 
groove where it is well separated from the negatively charged phosphate 
groups on either side. 
I.2.8. The Mechanism of RNA and DNA Synthesis Inhibition by Daunomycin 
and Its Analogs 
I.2.8.1. Inhibition of RNA Synthesis 
The formation of a complex between template DNA and RNA poly-
rnerase is essential for the synthesis of RNA (Hinkle et al., 1972a-d). 
It was found that daunomycin has no effect on the activities of the RNA 
polymerase enzyme per se, since the pre-incubation of the enzyme with 
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the inhibitor in the absence of the template does not affect the activity 
of the polymerase (Zunino et al., 1974). Base on these information it 
seems that the reduction of RNA polymerase activity could then be account-
ed for by the loss of template activity of the drug-treated DNA. The 
finding that daunomycin causes a marked drop in the formation of a com-
plex between RNA polymerase and DNA template (Mizuno et al., 1975) indi-
cates that the binding of daunomycin to DNA may give rise to steric hin-
drance effects that interfere with the association of the template to RNA 
polymerase and thus, result in RNA synthesis inhibition. Experimental 
support comes from the finding that there is a competitive inhibition of 
daunomycin and DNA template in RNA synthesis in which inhibition can be 
overcome by readdition of the template (Zunino et al., 1974). On the 
contrary, a non-competitive relationship was established between the drug 
and the RNA polymerase enzyme, indicating that the inhibition is pre-
dominently due to the interaction of daunomycin with template DNA. It 
2+ 
was also noted that Mg could reverse the inhibitory effect of dauno-
mycin in RNA synthesis presumably by releasing the drug from the drug-DNA 
complex (Calendi et al., 1965) thereby freeing the DNA template so that 
it can be associated with RNA polymerase for transcription. All of these 
results suggest that the inhibition is due to the formation of a reversi-
ble inhibitor-DNA complex which reduces the capacity of DNA to bind RNA 
polymerase. 
The mechanism of RNA polymerase inhibition by daunomycin has 
also been studied in terms of the preferential binding of the drug to 
specific base pairs of the template, but the results from such reports 
have conflicted. Studies with DNA obtained from different sources 
revealed that the binding of daunomycin to DNA increases as the G-C 
content of DNA increases (Zunino, 1971). Kersten also reported that 
the conformational changes of the daunomycin chromophore upon complex 
formation with DNA are slightly dependent on the G-C content of DNA 
(Kersten et al., 1971). However, inhibition studies of the DNA-
dependent RNA polymerase by daunomycin (Ward et al., 1965) showed that 
daunomycin inhibits DNA-dependent RNA polymerase activity irregardless 
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of the G-C content of the template used. Recent reports, from the study 
of the interaction between daunomycin and short segments of double heli-
cal DNA (Rich et al., 1981), also indicate that although highly specific 
hydrogen bonds, which serve to hold the antibiotic to the double helix, 
can be formed between daunomycin and G-C base pairs, such bond do not 
suggest great selectivity, i.e., when adenine is present instead of 
guanine, different but still highly stable hydrogen bonds can also be 
formed with daunomycin. Furthermore, results from model building 
(Plumbridge et al., 1979) suggest that daunomycin has a preference for 
A-T sequence and the stabilization of double helix by daunomycin appears 
to be dependent on the A-T content in DNA (Zunino et al., 1974). Other 
inhibition studies also showed that DNA templates which contain poly(dA· 
dT) are more sensitive to the action of daunomycin (Bhuyan et al., 1965). 
These results are supported by the observations that the inhibitory action 
of daunomycin is most effective at later stages of cell division (later 
S, G2 and M) in mammalian system (Mizuno et al., 1975; Silvestrini et al., 
1970). At this stage the drug preferentially binds to the heterochromatin 
fraction which is rich in adenine-thymine (Yunis et al., 1971}. In addi-
tion, studies with synchronized rat fibroblasts (Silvestrini et al., 1970) 
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showed that the high sensitivity of RNA synthesis to daunomycin in G2 
phase is related to the fact that DNA containing poly (dA•dT) sequences 
are being transcribed at this time (Becker, 1972). It seems, therefore, 
that the extent of inhibition may be not only a function of the base com-
position of DNA but also of the secondary structure of DNA (Bram, l97la) 
as well as the complexity of nucleotide sequence (Bram, l97lb) of the 
DNA segment that is being transcribed. 
The regulation for gene expression (via transcription) in eukary-
otic cells appears to involve multiple forms of RNA polymerase (Widnell 
et al., 1966). It was discovered that RNA polymerase A (or I), which is 
located in the nucleolus, is responsible for the synthesis of rRNA. RNA 
polymerase B (or II), which is located in the nucleoplasm is responsible 
for the general synthesis of mRNA. These enzymes can be distinguished by 
their sensitivity to ~-amanitin; RNA polymerase A is insensitive, RNA 
polymerase B is completely inhibited (Chambon, 1975). Also, RNA poly-
2+ 
merase A is activated by Mg whereas RNA polymerase B is activited by 
It was discovered that daunomycin preferentially inhibits the 
incorporation of tritiated uridine into ribosomal RNA components (Dana 
et al., 1972). The synthesis of heterodisperse, high molecular-weight, 
nucleoplasmic RNA has little sensitivity to inhibition by daunomycin, 
whereas the synthesis of tRNA, SS ~~A, and two small molecular-weight 
RNA components (Components C and D) shows medium sensitivity to dauno-
mycin. In contrast, daunomycin inhibits the synthesis of l8S and 28S 
rRNA and the nuclear 45S and 32S precursors strongly and to the same 
extent, indicating that it is the synthesis of 45S RNA that is inhibited 
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and not the processing of 45S RNA to rRNA. This preferential inhibition 
of rRNA by daunomycin is supported by electron microscopic studies 
(Rusconi et al., 1964) and autoradiographic studies (DiMarco et al., 
1965) in Hela cells. One explanation for this preferential inhibition 
is found in the findings that heat denatured DNA is more transcribed than 
the native DNA by RNA polymerase B (Barthelemy et al., 1976) and it takes 
much higher concentration of daunomycin to inhibit RNA polymerase acti-
vity using denatured DNA as template (Zunino et al., 1975). This is an-
other piece of indirect evidence to support the intercalative theory of 
inhibition in which the double-stranded DNA is required for strong bind-
ing and inhibition. Native DNA, on the other hand, is a better template 
for RNA polymerase A and thus is inhibited by the intercalating dauno-
mycin to a much greater extent. 
Some preliminary proposals for the mechanism of RNA synthesis 
inhibition by daunomycin have been reported. Daunomycin has been found 
to reduce the formation of a complex between RNA polymerase and DNA be-
cause the drug-DNA complex provides the template a different conforma-
tion which is unable to bind RNA polymerase (Mizuno et al., 1975; Section 
I.2.8.1.). A later study with DNA extracted from Ehrlich Ascites tumor 
cells (Barthelemy et al., 1976) revealed that the presence of daunomycin 
also greatly increases the rate of dissociation of the enzyme-template 
complex. It was speculated in this study that daunomycin probably inter-
feres with the melting of the double stranded DNA by RNA polymerase at 
the binding site (which transforms the enzyme-DNA complex into a stable 
one for RNA synthesis initiation, (Meilhac et al., 1972; also see Section 
I.3.4., and Figure 6)) and therefore de-stabilizes the enzyme-DNA complex 
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for RNA synthesis. 
Since elongation of RNA strands does not seem to be affected 
significantly by daunomycin (Schellinx et al., 1979), it appears that 
once the first phosphodiester bond is formed, dissociation of daunomycin 
from the opened helix is fast enough not to be rate limiting. 
I.2.8.2. Inhibition of DNA Synthesis 
Very little effort has been made in the study of the mechanism 
of DNA polymerase inhibition by daunomycin or adriamycin. The currently 
available information is at best conflicting and inconclusive. For ex-
ample, in a system using salmon spearm DNA and T4 DNA polymerase (Goodman 
et al., 1974; Goodman and Lee, 1977) it was determined that DNA synthesis 
is inhibited by adriamycin via inactivation of the template functions. 
Both intercalative and ionic types of binding of the drug to DNA were 
found to occur and the relative amounts of each type of binding may de-
pend upon the relative drug to DNA ratio. At low drug to DNA ratio, the 
intercalation is favored, while at high drug to DNA ratio, the ionic 
interactions become additional forces for DNA synthesis inhibition. 
A separate study (Tanaka et al., 1980) showed that inhibition of 
DNA synthesis by daunomycin and adriamycin is mainly the result of direct 
interaction of drug molecules with DNA polymerase rather than the result 
of drug impairing of the template activity of DNA due to intercalation. 
Apparently stronger inhibition is produced by pre-incubating the drugs 
with enzyme rather than with the template-primer complex. 
The reason for the discrepancies between these results is not 
clear. It is apparent, however, that the mechanism of inhibition of 
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both RNA and DNA synthesis by daunomycin and its analogs are still poorly 
understood. Additional studies are necessary to determine the mechanism 
of the inhibition process and to resolve conflicting reports. 
I.2.8.3. Factors Affecting the Inhibition Studies 
Conflicted results have also been reported on the comparative 
study of the extent of inhibition by daunomycin in the incorporation of 
labeled precursors into RNA and DNA in vivo or in cultured cells. 
-- ----
In vitro studies on Ehrlich ascites tumor cells (Dano et al., 
1972) and on Ll210 mouse leukemia cells (Meriwether et al., 1972) showed 
that daunomycin inhibits DNA and RNA synthesis to a similiar degree. 
Other in vivo studies support this result (Rusconi et al., 1969; Meri-
wether et al., 1972). However, some studies showed that DNA polymerase 
is more sensitive to daunomycin inhibition than RNA polymerase (Mizuno 
et al., 1975; Momparler et al., 1976). These discrepancies may be due 
to the different experimental conditions employed, since studies with 
Hela cells demonstrated that at low daunomycin concentrations RNA syn-
thesis is more inhibited than DNA synthesis whereas at high drug con-
centrations both DNA and RNA synthesis are inhibited to the same degree 
(Rusconi et al., 1969). 
Cell population densities also affect the response of the cells 
to inhibition. In fact, the inhibition of RNA or DNA synthesis is lower 
when then cell number is relatively high even though the relative uptake 
or the amount of daunomycin bound to DNA remains the same as when the 
cell number is relatively low. Autoradiographic studies have provided 
evidence that, in synchronized cells, the uptake of the antibiotic also 
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varies according to the phase of the cell cycle (Silvestrini et al., 
1963). 
Discrepancies have also been reported on the relative inhibitory 
potency of daunomycin and adriamycin. Evidence from cell culture (Meri-
wether et at., 1972) and cell free systems (Zunino et al., 1975) show 
that even though daunomycin and adriamycin inhibit both DNA and RNA 
synthesis to the same extent, daunomycin appears to be a better inhibitor 
in cell culture than adriamycin whereas adriamycin appears to be a better 
inhibitor in the cell free systems. However, it was shown that the up-
take of daunomycin by the cells is much greater than that of adriamycin, 
indicating that the actual effectiveness of adriamycin could be higher 
than that of daunomycin. Some in vivo studies with animals (Sandberg 
et al., 1970) and preliminary clinical studies (Bonadonna et al., 1970) 
showed a higher therapeutic index for adriamycin. 
All of these studies have lead to the conclusion that the un-
derstanding of the mechanism of daunomycin action is still far from clear 
and that more than one mechanism of inhibition could be operating in the 
intact animals. For example, mechanisms involving differences in the 
rates of drug uptake and routes of drug excretion, differences in pro-
tein binding, differences in metabolic pathways, or different rates of 
metabolism in vivo for each drug probably play important roles in deter-
mining the overall drug effectiveness in vivo. 
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I.3. Mechanism of Transcription 
DNA-dependent RNA polymerase is responsible for the synthesis of 
all cellular RNA and thus plays a central role in the process by which 
the genetic information encoded in DNA is expressed. The information 
presented in this section pertains to bacterial RNA polymerase, unless 
specified otherwise. 
The prokaryotic transcriptional process catalyzed by bacterial 
RNA polymerase can be formally separated into several steps, including 
binding of the enzyme to the template, initiation steps which yield a 
tight complex of RNA polymerase with the promoter and opening the double-
stranded structure at specific sites allowing the formation of the first 
phosphodiester bond. This is followed by elongation using one strand as 
a template to direct the synthesis of a complementary RNA molecule, and 
finally termination, in which the product RNA is liberated and the enzyme 
becomes available for the next cycle (Zillig et al., 1976). 
I.3.l. Structure and Composition of Bacterial RNA Polymerase 
Bacterial DNA-dependent RNA polymerase is a multisubunit enzyme. 
Holoenzyme monomers from various sources contain two large subunits, ~· 
and ~ (molecular weight 160,000), two identical small subunits,~(molecular 
weight 40,000), and an initiation factor, 6(molecular weight ranging from 
44,000 to 92,000 (Lill et al., l975a; Palm et al., 1975)). Holoenzyme 
(~·~~26) can be separated into two functional parts: a core enzyme 
(~·~~ 2 ) which is able to initiate RNA synthesis but lacks the ability to 
initiate such synthesis at specific sites on the template (Chamberlin, 
38 
1976}; and the sigma factor (6), which enables the enzyme to select a 
specific initiation site on the template (Burgess, 1971) by recognizing 
a particular base sequence termed "promoter". The sigma factor is re-
leasedduring chain elongation (Travers and Burgess, 1969). The recon-
sitution of holoenzyme from these two components occurs rapidly when 
the two are mixed in solution (Berget al., 1971) and the reconstituted 
holoenzyme regains the ability to initiate specific RNA chains. 
I. 3. 2. Functions of the Subunits of RNA Polymerase 
Dissociation of the enzyme with SDS or high concentration (SM) 
of urea leads to complete separation of all the subunits of the enzyme; 
these subunits can then be resolved from each other by electrophoresis or 
acrylamide gel or by sizing chromatography (Travers and Burgess, 1969; 
Heiland Zillig, 1970). 
~·,the most basic subunit of RNA polymerase (Rexer et al., 1975) 
is able to bind to DNA whereas the other subunits which are less basic, or 
the subassembly ~~2 (Fukuda et al., 1974: Yarbrough et al., 1974) do not 
bind to DNA. Therefore ~· has been designated as the DNA-binding subunit 
(Sethi et al., 1971). Heparin, a polyanionic transcription inhibitor, 
binds to the~· subunit (Zillig et al., 1971) and competes with DNA for a 
template binding site on the polymerase (Walter et al., 1967) and there-
fore provides further evidence for the DNA binding function of ~· subunit. 
It has also been shown (Stetter et al., 1974) that~· contains a binding 
site for~- During transcription ~is released from the active complex 
of RNA polymerase, template and product when the product has reached a 
critical length of about ten nucleotide residues (Krakow et al., 1971). 
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It has been suggested that~ is bound to the "product site" of the enzyme 
(which might involve~') and is displaced by the growing RNA strand 
(Zillig et al., 1976). 
The understanding of the functional role of ~ subunit comes from 
the studies involving rifampicin which binds to RNA polymerase (Wehrli 
et al., 1968) and inhibits the initiation of RNA synthesis (Sippel et al., 
1968). RNA polymerases from mutants resistant to the drug do not bind 
the drug and show a ~ subunit with an altered electrophoretic mobility 
(Rabussay et al., 1969). ~subunit also has been found to be directly 
involved with streptolydigin, another antibiotic which interacts with 
core RNA polymerase and inhibits elongation of RNA chains (Siddhikol et 
al., 1969). Therefore the~ subunit contains the antibiotic binding 
sites and is responsible for the catalytic functions (both initiation and 
elongation) of the enzyme. 
Subunit cJ.. is present in solution as a dimer (Lill et al., l975b) 
in which the twodchains are linked by a disulfite bridge (Zillig et al., 
1976). The function of o<. is not clear at the moment, although it has been 
suggested that in addition to ~, ~ and ~· are required for reconstitution 
of the catalytically active holoenzyme (Chamberlin, l974a) and~ is re-
quired to bind~ in order to activate~ for drug binding (Lill et al., 
l975a). 
These assignments of specific functions to the various subunits 
are still somewhat tentative, particularly due to the lack of knowledge 
about the primary and three dimensional structure of the enzyme. 
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I.3.3. Binding of RNA Polymerase to DNA 
In the presence of an excess of RNA polymerase, whether it be 
halo- or core-enzyme, helical DNAs such T7 can bind an amount of RNA 
polymerase limited only by the steric interactions between enzyme mole-
cules (Pettijohn et al., 1967). Hence RNA polymerase possesses a sub-
stantial general affinity for DNA that is not sequence-specific (Hinkle 
et al., 1972a). This general affinity is called the non-specific bind-
ing and is entirely electrostatic in nature (Record et al., 1976). The 
binding constants for either core- or holo-enzyme are not highly tempera-
ture sensitive, indicating that the bindings do not involve opening (or 
melting) of DNA base pairs (Saucier and Wang, 1972). The association 
constant for general binding of RNA polymerase holoenzyme and core-
8 9 -1 11 -1 
enzyme to T7 DNA were estimated at 10 -10 M and 10 M respectively 
2+ + 
under normal reaction condition in 0.01 M Mg and 0.05 M Na (Hinkle 
and Chamberlin, 1972a). The substantially higher binding constant for 
core enzyme than that for holoenzyme suggests that binding of sigma sub-
unit supresses the general binding affinity of core polymerase for DNA 
(Chamberlin, 1974b) except at promoter sequences (see next section). 
Core polymerase is able to catalyze the synthesis of RNA chains 
but is unable to locate promoter sites to form the highly stable RNA 
polymerase-promoter complexes with DNA template. Therefore core-poly-
merase-DNA complexes are highly sensitive to attack by heparin (Hin-
kle et al., 1972c) and rifampicin (Bautz and Bautz, 1971), which indi-
cates a slow rate of RNA chain initiation by these complexes. It was 
also found that single-stranded breaks are the primary sites for initia-
tion by core enzyme (Hinkle et al., 1972c) probably because of the fact 
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that DNA-core enzyme complexes are defective in opening the DNA strands, 
which is necessary in transcription (Saucier and Wang, 1972). 
!.3.4. Site Selection of RNA Polymerase Holoenzyme 
In systems where RNA polymerase carries out selective transcrip-
tion, effective binary complexes are formed primarily at promoter regions 
of the DNA template. The specificity of the process of "site selection" 
involves the binding interaction which positions RNA polymerase on the 
template and the subsequent interactions between the enzyme and DNA at 
that site that render the complex effective in the chain initiation re-
action. This process of promoter "site slection" is a key point at which 
cellular regulation of transcription takes place. 
Under appropriate reaction conditions, RNA polymerase holoenzyme 
and DNA template form stable binary complexes which can go on synthesizing 
RNA with spe~ific 5'-termini (Pribnow, 1975). The formation of these 
stable complexes is dependent upon the rapid dissociation of the non-
specific complexes mentioned in the last section. Studies from T7 DNA 
and E. coli RNA polymerase holoenzyme showed that a maximum of eight 
enzyme molecules are tightly bound to T7 DNA with a binding constant of 
12 14 -1 . 10 -10 M (H~nkle et al., 1972a). A limited number of base pairs 
(six to seven) are opened in the complex (Saucier and Wang, 1972) with 
the RNA polymerase acting as a sequence-specific melting protein (Mangel 
and Chamberlin, 1974a). This opening process is temperature dependent 
and the complexes formed have been termed "open promoter complexes" 
(Mangel and Chamberlin, 1974b). 
With T7 DNA, open promoter complexes are not formed at low tern-
perature; as the temperature is increased, however, there is a coopera-
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tive transition with a midpoint of about 18 °C (transition temperature), 
and above this temperature complex formation is eventually complete (Man-
gel and Chamberlin, l974a). The enthalpy for this melting reaction is 
calculated at 57 Kcal per mole (Mangel and Chamberlin, l974a). This 
opening is essential to the subsequent binding of the nucleoside tri-
phosphates in the chain initiation step (Chamberlin, 1976). 
In conclusion, the sequence of steps in site selection by RNA 
polymerase holoenzyme involves (l) reversible, weak binding to random 
sites on DNA to form non-specific complexes, leading to (2) attachment 
to a site at or near the specific site (promoter) on the T7 DNA molecule 
to form the closed promoter complex (I complex) and (3) a reaction to 
form a highly stable complex, the open promoter complex (or RS complex) 
with the separation of the DNA strands at or near the promoter sites 
(Zillig et al., 1971). The open promoter complex is able to initiate the 
formation of the first phosphodiester bond to form the OP complex. A 
scheme depicting all these pre-initiation events is presented in Figure 6. 
I.3.5. Assays for the Rate of RNA Initiation 
Several assays for the rate of RNA chain initiation have been 
developed (Mangel and Chamberlin, l974a,b,c) by exploiting the property 
of the drug rifampicin to attack and inactivate RNA polymerase molecules. 
It was discovered that both free E. coli RNA polymerase and RNA poly-
merase bound to T7 DNA template are attacked by rifampicin in second-
order reactions although the rate constant for the latter is 100-fold 
slower (Hinkle et al., l972d). In contrast, the elongating enzyme mole-
cules are insensitive to the attack of rifampicin (Sippel and Hartman, 
Figure 6. Promoter Recognition and Initiation of RNA 
Synthesis 
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1. Intermolecular Exchange 
(non-specific complexes) 
ppp 
4. Initiation 
(OP complex) 
2. Initial Recognition 
(I complex) 
ATP, GTP, UTP,CTP 
3. Activation 
(RS complex) 
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1968). 
Another important feature in these assays is the time under 
which the RNA synthesis is allowed to proceed. The in vitro transcrip-
tion of T7 DNA by E. coli RNA polymerase is restricted to the early 
region consisting of about 20% of the r-strand of the T7 duplex (Davis 
and Hyman, 1970), which yields an RNA product of approximately 7,000 
nucleotides long (Millette et al., 1970). Since the rate of the chain 
growth is rapid (about 40 nucleotides per second for T7 DNA (Davis and 
Hyman, 1970)), termination and re-initiation could take place within a 
few minutes. Therefore the reaction time in these assays is limited to 
90 seconds to eliminate the possibility of termination and re-initiation. 
Utilizing this information two assays were developed to measure 
the rate of I complex to RS complex transformation and the rate of RS 
complex to OP complex transformation. The detailed descriptions of these 
assays are presented in section III.3.4.2. 
I.3.6. Other Properties for Promoter Sites 
The formation of open promoter complexes is affected by the 
structure of the RNA polymerase involved, the structure and nucleotide 
sequence of the DNA template, other components present in solution and, 
finally, the reaction temperature. 
The open promoter complex has a high stability to dissociation 
with half-lives of many hours under standard ionic conditions (0.01 M 
2+ + 
Mg , 0.05 M Na ) . At low temperature or high ionic strength, the 
stability of the complex is greatly reduced (Seeburg and Schaller, 1975). 
The RNA polymerase in open promoter complex is monomeric (Beabealashvilly 
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et al.,l972) and is attacked at a reduced rate by rifampicin (Hinkle and 
chamberlin, 1972d) and polyanion heparin (Zillig et al., 1971). It is 
able to initiate an RNA chain rapidly when presented with nucleoside tri-
phosphate substrates (Mangel and Chamberlin, 1974c). 
Promoter sites display a definite specificity for a particular 
RNA polymerase. The T7-specific enzyme, for example, does not utilize 
any of the promoter sites on T3 DNA that are read by the T3-specific 
enzyme (Golomb and Chamberlin, 1974), nor does it read E. coli RNA poly-
merase promoter sites on T7 DNA. Therefore, each promoter has the se-
quence information essential for its utilization by a particular RNA 
polymerase (Chamberlin, 1976). 
Promoter sites on the same DNA differ in their rates of utili-
zation (Heyden et al., 1972). With T7 DNA, for example, a major fraction 
of the RNA formed with E. coli RNA polymerase at low ratios of enzyme to 
DNA is initiated at three closely linked promoter sites (Al, A2, A3) at 
the early region of the molecule (Dunn and Studier, 1973; Daussee et al., 
1972). These three sites are used with approximately equal effeciency at 
37°C, but at low temperature (10-l5°C) or high ionic strength of the re-
action mixture, site A3 is used over 50% of the time (Daussee et al., 
1972). In addition to these so called "major" promoter sites, "minor" 
promoter sites, which are used with lower effeciency except when excess 
enzyme is present, are also located in the early region of the T7 genome 
(Minkley and Pribnow, 1973), but it is not known whether these sites are 
functional in vivo. 
Major promoter sites can also differ from the minor sites in the 
strength of the melting interaction between the promoter and the RNA 
polymerase. Under conditions which reduce the melting reaction (i.e., 
low temperature) a major promoter will be read at a reduced rate and 
becomes a minor promoter (Richardson, 1975). At higher temperatures 
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or in the presence of DNA de-stabilizing agents these promoters are ac-
tivated and begin to be read at a substantial rate (Richardson, 1975; 
surzycki, 1976). However, for some minor promoters, conditions that 
facilitate the melting interaction do not alter the relative rate of 
reading (Golomb, 1974b). 
For certain promoter sites, such as that governing the lac 
operon, transcription by E. coli RNA polymerase alone is very slow unless 
a cyclic AMP receptor protein is added along with cyclic AMP (Chen et 
al., 1971; Anderson et al., 1974). The cyclic AMP receptor protein was 
found to reduce the melting temperature of DNA (Makanishi et al., 1974). 
This positive control protein is also known to be essential for trans-
scription in vivo (Chamberlin, 1976). 
Repressor proteins suppress transcription at specific promoter 
sites and block the formation of open promoter complexes by making the 
promoter inaccessable to RNA polymerase (Squires et al., 1976) or acting 
as anti-melting agents (Wang et al., 1974; Von Hippel et al., 1975). 
I.4. Purpose and Scope for This Research Project 
Recently the correlation between biological properties and 
pharmacological effectiveness of a series of anthracyclines has been 
examined. Many attempts have been made to establish a relationship 
between the effects of anthracycline bind to DNA and the resulting 
stabilization of the double helix versus the antitumor activities of 
the drugs. 
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Studies involving large number of structural analogs of 
daunomycin have shown that the strength of DNA binding correlates in 
general with antitumor activity (Nakanishi et al., 1974). Since the 
proposed mode of binding of anthracycline to DNA is intercalation, cer-
tain predictions regarding the DNA affinities of various daunomycin de-
rivatives have been made on the basis of the structure of the resulting 
anthracycline-DNA complex. For example, the C-4' hydroxyl of the anth-
racycline sugar moiety was found not to take part in any interactions 
and this suggests that epimerization at C-4' would produce derivatives 
with no alteration in their DNA binding ability (Neidle, 1977). This 
indeed was found to be the case with 4'-epiadriamycin which intercalates 
to DNA with the same affinity as its parent compound (Plumbridge and 
Brown, 1978) and has equivalent activity against experimental tumors as 
that of adriamycin (Arcamone et al., 1975). It was also predicted that 
since the C-4 methoxy carbon atom of daunomycin is not co-planar to the 
heterocyclic ring, removal of this group should allow deeper insertion 
of the ring into the intercalation site and therefore should increase 
the affinity to DNA (Zunino et al., 1976). Indeed 4-demethoxy derivatives 
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of daunomycin have been found to enhance the thermal stability of DNA 
to a larger degree than the parent compounds (Zunino et al., 1976). 
Furthermore 4-demethoxydaunomycin is as effective against various ex-
perimental tumors as the parent compound but at doses four to eight times 
lower than those effective for daunomycin (Arcamone et al., 1976). Simi-
larly, 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin are effec-
tive against the same experimental tumors but at doses ten times lower 
than those effective for adriamycin (DiMarco et al., 1978). Therefore, 
the present argument is that the structure of anthracyclines greatly 
influence their binding properties to DNA and these binding properties 
in turn correlate with the antitumor activities of these drugs (i.e., 
stronger binding increases antitumor effectiveness of the drug). 
Although there is very little doubt that DNA binding affects 
the antitumor activities of anthracyclines, there are now some indi-
cations that the strengths of association between anthracyclines and DNA 
(i.e.,the association constant) may not be the most appropriate para-
meters to explain the correlation. For instance, the higher potency of 
4-demethoxydaunomycin compared to daunomycin is not consistent with the 
similarity of the apparent association constants of these drugs with 
6 -l 6 -1 DNA, which are 2.4 + 0.3 x 10 M and 3.3 + 0.8 x 10 M respectively 
(Zunino et al., 1976). Other findings have shown that upon binding to 
DNA, anthracyclines stabilize the double helix (Zunino et al., 1972). 
This suggests that the extent of double helix stabilization may provide 
a better approach to correlate the biochemical and pharmacological acti-
vities of anthracyclines. In fact 4-demethoxydaunomycin has been found 
to be more effective in stabilizing the double helix than the parent 
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compound (Zunino et al., 1976). It should be noted that although this 
property is partially dependent on the strength of association between 
DNA and the drug, it is not strictly proportional to it. 
Furthermore, studies on the effectiveness of the four stereo-
isomeric 4-demethoxydaunomycin derivatives (Figure 7) as potential anti-
tumor agents have shown that inversions of configuration at position l 
of the amino sugar and at positions C-7 and C-9 of the heterocyclic ring 
markedly decrease demethoxydaunomycin binding to DNA, with the ~-anomers 
binding less strongly. In terms of double helix stabilization, the ~-
anomers are most effective with the 7,9-bis-epi derivatives producing 
the least amount of stabilization (Zunino et al., 1976). However, the 
--
inhibitory effects of these series of isomers on the in vitro synthesis 
of RNA correspond more closely to their stabilizing effects on the double 
helix rather than their binding affinities to DNA. 
Recently anthracyclines such as carminomycin, aclacinomycin, 
marcellomycin, and musettamycin (Figure lc, d, e, and f) have been iso-
lated or synthesized (Nettleton et al., 1977; Oki et al., 1975). Car-
minomycin has a similar structure with daunomycin while the other three 
anthracyclines are characterized by the presence of a carbomethoxy group 
at C-10 position and a glycosidic side chain containingfrom two to three 
sugar residues. The amino group of the primary sugar residue for these 
new anthracyclines is also substituted. It has been shown that daunomy-
cin, adriamycin and carminomycin inhibit RNA synthesis at comparable 
concentrations (DuVernay et al., 1980) whereas aclacinomycin, marcello-
mycin and musettamycin are more effective against RNA synthesis than the 
previous group (Crooke et al., 1977; DuVernay et al., 1979). However, 
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Figure 7. Stereoisomers of 4-demethoxydaunomycin 
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4-demethoxydaunomycin 
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daunomycin o{-anomer 
I . 
1 
COCH3 
'OH 
OH 
OH 
OH I I 
I 
I 
f-0 
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the mechanisms of RNA synthesis inhibition by these drugs remain unknown. 
The mechanisms of RNA synthesis inhibition by ethidium bromide 
and its analogs have been thoroughly studied (Aktipis and Panayotatos, 
1977). These drugs were found to inhibit primarily the initiation process 
of RNA synthesis without affecting elongation to a significant extent. 
subsequently the effects of these drugs on the rate of RNA polymerase-DNA 
binary complex transformation processes prior to RNA synthesis initiation 
were carefully examined. It was concluded that even though no signifi-
cant differences were observed in the mechanism by which these drugs 
inhibit RNA synthesis, the relative inhibitory effectiveness of ethidium 
and its analogs depended not only on their relative binding affinities to 
DNA but on the individual structural characteristics of these drugs as 
well. Thus, it is reasonable to expect that structural differences 
between relatedanthracyclines may also influence the mechanism of inhibi-
tion of RNA synthesis to different extents, and that such differences may 
not all be due simply to differences in the affinity with which each 
anthracycline associates with the DNA template. 
Previous attempts to correlate the biochemical properties of 
anthracyclines, in terms of their DNA binding affinities and stabiliza-
tion of double helical structures, with the pharmacological effectiveness 
of these drugs have failed to provide consistent results. In addition, 
the mechanism by which anthracyclines inhibit RNA synthesis has generally 
been overlooked in these studies. It is the goal of this dissertation to 
examine the mechanism by which anthracyclines inhibit RNA synthesis. Once 
the mechanism of RNA synthesis inhibition by each anthracycline analog 
is determined, it would also be of interest to examine whether a correla-
tion between the mechanism of inhibition and the template affinities of 
these various anthracyclines can be established. 
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CHAPTER II 
MATERIALS AND METHODS 
II.l. Materials 
Bacteriophage T7 {host: E. coli B) was a generous gift from Dr. 
D. Hinkle of the University of Rochester {Rochester, New York 14627). 
11 The phage had a titer of 3.5 x 10 plaque forming units per ml. 
E. coli B thymine requiring mutant strain was a generous gift 
from Dr. Robert V. Miller of Loyola University of Chicago (Maywood, 
Illinois 60153). 
DNA-dependent RNA polymerase (Nucleosidetriphosphate: RNA nu-
cleotidyltransferase; EC No. 2.7.7.6) from E. coli B., strain K-12 was 
purchased from Sigma Chemical Company (St. Louis, Missouri 63178) as a 
solution in 50% glycerol and 50% 0.01 M Tris buffer, pH 7.9, containing 
0.1 M NaCl, 0.1 mMDithiothreitol and 0.1 mM EDTA. The enzyme (Lots 
108C-04491 and lOOF-00781) had specific activities of 1195 and 750 units/ 
mg, and consisted of 2.9mgproten/ml and 3.5 mg protein/ml, respectively. 
One unit of enzyme will incorporate 1 nMole of labeled ATP into an acid 
insoluble product in 10 minutes at pH 7.9 at 37°C, using Calf thymus DNA 
as template {Burgess, 1969). 
Daunomycin {(8S-cis)-8-acetyl-10-(~-amino-2,3,6-trideoxy-~-L­
lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxyl-l-methoxy-
5,12-naphthacenedione), a red crystalline solid, was purchased from 
Boehringer Mannehim Biochemicals (Indianapolis, Indiana 46250) as hydro-
chloride, with a molecular weight of 564.0 daltons (Lot No. 1457501). 
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4-demethoxydaunomycin (Lot No. GDA 2652/61) was a generous gift from 
Dr. Federico Arcamone of Farmitalia Carloerba, Milano, Italy. Crystal-
line solids of aclacinomycin (yellow, Lot No. 80Fl08), carminomycin 
(orange, Lot No. 80F401), marcellomycin (dark red, Lot No. C36145-S369-
G55) and musettamycin (dark red, Lot No. C36145-S420-G25) were generous 
gifts from Dr. J.L. MacBeth of Bristol Laboratories (Syracuse, New York 
13201). Marcellomycin and musettamycin were provided as free bases. 
Rifampicin (m.w. 823 daltons) was purchased from Sigma. 
White crystalline sodium salts of nucleoside triphosphates; 
ATP, CTP, GTP, and UTP were purchased from P-L Biochemicals, Inc. (Mil-
waukee, Wisconsin 53205). The commercial preparations were at least 97% 
pure according to the manufacturer's specifications. 
[5,6-3H] uridine-5'-triphosphate, tetrasodium salt (specific 
activity: 25 Ci/mmol) in ethanol:water (1:1) solution was purchased from 
ICN Pharmaceuticals, Inc. (Irvine, California 92715). The solvent was 
removed by directing a gentle stream of nitrogen gas onto the surface 
of the warmed solution (not exceeding 30°C) before use. 3 [Methyl- H] 
thymine agueous solution (specific activity 30 Ci/mmol) was purchased 
from Amersham Corporation (Arlington Heights, Illinois 60005). All 
radioactive materials were over 99% pure according to the manufacture's 
specifications. 
Nitrocellulose membrane filters (BA85, 24 mm, 0.45 micron) were 
purchased from American Scientific Products (McGaw Park, Illinois 60085). 
Whatman glass microfibre filters (GF/C, 2.4 em) were purchased from 
Sargent-welch (Skokie, Illinois 60077). 
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II.2. Instruments: 
The following instruments were used in this study: 
Cary model 15 Recording Spectrophotometer (Varian, Cary Instru-
ments Division, Monrovia, California 91016). 
Beckman model LS-65 Ultracentrifuge (Beckman Instruments, Inc. 
Fullerton, California 92634). 
Beckman model LS 7500 Liquid Scintillation Counter with Micro-
processor (Beckman Instruments, Inc. Fullerton, California 92634). 
Sorvall RC-5B Refreigerated Superspeed Centrifuge (Du Pont 
Instruments, Wilmington, Delaware 19898). 
Barnstead Laboratory Sterilizer (Sybron Coporation, Downers 
Grove, Illinois 60515). 
Corning model 12-B Research pH Meter (Corning Scientific 
Instruments, Medfield, Massachusetts 02052). 
Mettler Pl63 Balance (Mettler Instrument Corporation, Highstown, 
New Jersey 08520). 
Perkin-Elmer model 320 Spectrophotometer (Perkin-Elmer Corpora-
tion, Norwalk, Connecticut 03016). 
Pipetman Adjustable Pipet models P-1000, P-200, P-20 (Rainin 
Instrument Co. Inc. Woburn, Massachusetts 01801). 
Forma model 2563 Shaker Bath (Forma Scientific, Marietta, Ohio 
40133). 
II.3. Preoaration of Working Solutions 
II.3.l. Preparation of T7 DNA 
Bacteriophage T7 was grown essentially as described by C.C. 
Richardson (Richardson, 1966). E. coli B was grown in a TCG medium 
(Thomas and Abelson, 1966) (0.8 ml, O.lOM Na 2so4 ; 450 ml H20; 0.5 ml, 
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1.0 M MgS04 ; 1.0 ml, 25% NaCl; 0.1 ml, 0.5 M CaCl2 ; 1.5 ml, l mMFeCl 3 ; 
3.2 ml, 0.1 M KH2P0 4 ; 50.0 ml, 1.0 M Tris-HCl, pH 7.4; 5.0 ml, 10% 
glucose; 5.0 ml, 5% Casamino acids) in a culture flask with rapid swir-
ling at 37°C. T7 phages were added to the medium at a multiplicity of 
0.1 when E. coli B had reached log phase. Shaking was continued for 1 
hour at 37° C to permit complete lysis of the cells. The lysate was 
centrifuged for 15 minutes at 10,000 g and the precipitate was discarded. 
A rapid bacteriophage sedmientation method (Yamamoto and Alberts, 
1970) was employed to purify and collect the phage particles. The crude 
lysate was cooled to 4° C and enough NaCl was added to bring its con-
centration up to 0.5 M. Polyethylene glycol (PEG 6000) 6% (w/v) was 
added into the crude lysate and the solution was let stand for at least 
l hour at 4° C. The phage pellet was collected after centrifugation at 
10,000 g for 15 minutes and was resuspended in a minimum amount (l ml) of 
sterile lMNaCl, 0.01 M Tris buffer (pH 8.0). The phage suspension was 
then purified by CsCl density gradient equilibrium centrifugation. 
Sterile CsCl solutions of densities 1.1, 1.3, 1.5 and 1.7 g/ml (5 ml 
each) were added in succession by introduction at the bottom of the tube. 
The phage suspension was then layered on top of the CsCl solutions. 
After centrifugation for 3 hours at 22,000 rpm and then 12 hours at 
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35,000 rpm the purified phage was collected and dialyzed overnight 
against 0.1 M potassium phosphate buffer (pH 7.5) containing 0.1 M NaCl. 
over 95% of the pure phages were reported to be recovered using the PEG 
precipitation method (Yamamoto and Alberts, 1970). 
T7 DNA samples were prepared by phenol extraction (Thomas and 
Abelson, 1966) of purified T7 phages. The purified phage solution was 
diluted to an optical density between 5 and 15 in a sterilized test tube 
and was shaken (60 rev/min) with equal volume of freshly distilled puri-
fied phenol (saturated with a 0.1 M potassium phosphate buffer, pH 7.5, 
containing 0.1 M NaCl) for 45 minutes at room temperature. The tube was 
then cooled to 4° C and centrifuged for 5 minutes at 3,000 rpm in an IEC 
clinical centrifuge to separate the two phases. The phenol layer (the 
bottom one) was removed with a Pasteur pipet and the DNA solution was 
dialyzed exhausively against the original buffer and finally against 
0.01 M Tris-HCl buffer (pH 7.8) containing 0.05 M KCl. This T7 DNA 
preparation was used without further purification. 
3 H-labeled T7 DNA was isolated from phages grown in the presence 
of [methyl-3H] thymine using thymine-requiring mutant of E. coli B as host 
in a M-9 minimal medium (l gNH4Cl, 3 g KH2Po4 , 6 g NaHP0 4 , 4 g glucose and 
l ml of l M MgS04 in one liter of water) supplemented with 2~g unlabeled 
thymine/ml. 3H-thymine (30 Ci/mmol) was added to the culture l hour 
before infection. The steps for purification of the 3H-labeled phage 
particles and the extractions of 3H-labeled T7 DNA were identical as 
before. 
The concentrations of T7 DNA, when designated as DNA-P, are 
expressed as equivalents of nucleotide phosphorus, and were determined 
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spectrophotometrically using a molar extinction coefficient of 6750 
with respect to phosphorus at 260 nm (Richardson, 1966). The A260 /A280 
ratio of the purified T7 DNA was 1.91 and the A260 ;A230 ratio was 2.35, 
indicating low protein contamination (Thomas and Abelson, 1966). 
rr.3.2. Preparation of Drug Solution 
Working solutions of all anthracyclines were prepared by dis-
solving these compounds in water. Aqueous solutions of marcellomycin and 
musettamycin were prepared by wetting the drug crystals with DMSO, 
followed by addition of water. Drug concentrations were determined 
spectrophotometrically using the molar extinction coefficients (Liter• 
-1 -1 Mole •em ) listed in Table 1. Fresh drug solutions were prepared 
for each experiment. 
Rifampicin stock solutions were prepared by dissolving 1 mg of 
rifampicin into 10 ml of 0.04 M Tris-HCl buffer, pH 7.9. The stock 
solutions were further diluted with the buffer to the desirable concen-
trantions in each experiment. 
II.3.3. Preparation of Nucleotide Substrates 
Unlabeled nucleoside triphosphate solutions were prepared by 
dissolving ATP, CTP, GTP and UTP sodium salts (5 mM each) in 0.04 M Tris-
HCl buffer, pH 7.9. Radioactively labeled substrates were made by dis-
solving nitrogen-dried (section II.l.) 3H-UTP (specific activity 0.02 
~Ci/nmole) in unlabeled nucleoside triphosphate solutions. These sub-
strate preparations were used immediately and no substrate solutions 
were used after two weeks of preparation. 
61 
II.3.4. Preparation of RNA Polymerase Solution 
It has been shown that under 37° C temperature, transcription 
of T7 DNA by E. coli RNA polymerase takes place primarily at three major 
promoter sites at the left end of the genome (Stahl and Chamberlin, 1977). 
since under the conditions mentioned above, for every four molecules of 
E. coli RNA polymerase only one will bind to the major promoter site on 
T7 DNA, 12 molecules of E. coli RNA polymerase are required to saturate 
the three type A promoter sites on one molecule of T7 DNA. Therefore, 
unless specified otherwise, a ratio of 12 polymerase molecules per T7 DNA 
molecule was used in all the experiments in this study. 
RNA polymerase obtained commercially was diluted with buffer 
solutions specified in each experiment so that during the assay appro-
ximately 1 pg of enzyme proteinwasmixed with 170 uM DNA-P to meet the 
molar ratio of 12 to 1. 
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II. 4. Methods 
II.4.l. Determinations of Binding Parameters for Anthracyclines 
In order to study the effect of anthracyclines on RNA synthesis 
at the molecular level, a quantitative measurement of the drug bound to 
T7 DNA under the assay conditions and temperatures must be obtained for 
each drug. 
The interaction of a large polymeric molecule DNA with small 
molecules of drug involves multiple binding sites so that DNA interacts 
simultaneously with more than one drug molecule. Each binding site on 
DNA is characterized by an apparent association constant, K 
app 
[occupied sites]/[unoccupied sites] [free drug]. If n is the maximum 
number of binding sites per DNA nucleotide and rb is the number of 
drug molecules bound per DNA nucleotide at a free drug concentration of 
[If] (moles/1), then for one type of site and in the absence of mutual 
interaction, the following equation could be obtained. 
= K n - K • r 
app app b (l) 
Scatchardplots (Scatchard, 1949) are constructed by plotting 
rb/If vs rb which yield a straight line with a slope of -Kapp The values 
of the apparent association constant (K ) and the maximum number of 
app 
binding sites per DNA nucleotide (n) can then be obtained from the slopes 
and the intercepts. 
The spectrophotometric method of Peacocke and Skerett (Peacocke 
and Skerett, 1956) was used to determine the apparent binding constant 
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and the maximum number of binding sites per DNA nucleotide for each drug 
on T7 DNA. This method is based on the observation that when ligands 
bind to nucleic acids, there is a change in the absorption spectrum of 
the ligand and this change is dependent upon the concentration of the 
nucleic acids. 
If the total concentrations of DNA and drug are denoted as [DNA] 
and [I ] respectively, then the equation 
0 
(2) 
can be derived in which rb[DNA] is the amount of drug bound to DNA, 
(or [Ib]). If A
0 
denotes the absorbance of free drug (when rb = 0, or 
[DNA] = 0, all drug molecules are in free form and A becomes the 
0 
absorbance obtained when only drug molecules are present in solution), 
~ denotes the absorbance of the bound drug (when all drug molecules are 
bound, then [If]= 0 and rb[DNA] = [I
0
]), and Ax is the absorbance of a 
mixture of free and bound drug, then 
[If] rb. [DNA] 
A = A + ~-X [I ] 0 [I ] 
0 0 
(3) 
If b is the fraction of total drug bound to DNA or 
rb• [DNA] 
b (4) 
[I ] 
0 
then from equations (2), (3) and (4), equation (5) can be derived. 
b = 
A 
0 
A 
0 
- A 
X (5) 
The amount of drug molecules in free form ([If]) can also be obtained 
from equations (2) and (4). Therefore 
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In the binding experiments, T7 DNA was mixed with a binding 
buffer (0.04 M Tris-HCl, pH 7.9, 0.02 M MgC1 2 , 0.01 M 2-mercaptoethanol). 
The concentration of DNA-phosphorus was determined spectrophotometrically 
with a Perkin-Elmer 320 spectrophotometer at 260 nrn, using a molecular 
extinction coefficient of 6750. Solutions of increasing DNA to drug 
ratios were prepared by adding increasing amounts of drug. The reaction 
mixtures were brought to the same final volume (2 ml) with binding 
buffer. Identical preparations containing equal DNA concentration but 
no drug were also prepared and used as reference. 
Since only limited amounts of T7 DNA (approximately 1.5 roM) was 
obtained from each preparation, the amount of drug (approximately 20 
pM) was chosen so that at the highest DNA to drug ratio, a maximal 
change in the visible spectrum due to drug binding to DNA could be 
obtained. One of the helpful features of the Perkin-Elmer 320 spectro-
photometer was that its absorbance scale could be adjusted as desired. 
Therefore, the absorbance at A for the solution containing total drug 
max 
concentration [I], but in the absence of DNA, could be expanded to full 
0 
scale, thus providing more accurate readings of the absorbance. 
The reaction solutions were incubated for ten minutes at 37° C 
for thermal equilibration and the difference absorption spectra were 
obtained versus the corresponding reference solutions. 
The absorbance of each sample (A ) and total drug concentration 
X 
in the absence of DNA (A ) were obtained from the recorded spectra at a 
0 
wavelength chosen so that A - A was maximum. The absorbance of drug 
0 X 
totally bound to DNA (~) could be obtained from the absorbance of a 
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solution prepared with very high DNA concentration, assuming that all 
drug molecules are bound under this condition. However, since high DNA 
concentration required for this purpose caused scattering and introduced 
error into the subsequent calculations, the graphic method of Li and 
Crothers (Li and Crothers, 1969) was used to obtain ~· This method 
showed that a plot of 1/A -A vs 1/[DNA]-[I ] yielded a straight line 
0 X -- 0 
with an intercept on the ordinate equal to l/A0-~. From the value of 
the intercept, ~ may then be calculated. 
II.4.2. Nitrocellulose Filter Assay for the Binding of RNA Polymerase 
to DNA 
Binding of RNA polymerase to DNA was measured using a modifica-
tion of the procedure of Jones and Berg (Jones and Berg, 1966). RNA 
polymerase solution was prepared by diluting commercial enzyme prepara-
tion with binding buffer (10 mM Tris, pH 8.0; 10 mM MgC1 2 ; 50 mM NaCl; 
10 mM 2-mercaptoethanol; 1 mM EDTA; and 1 mg BSA/ml). The reaction 
3 
mixture contained 10 pl of H-T7 DNA (final concentration of 170 pM 
DNA-P) , 80 pl of binding buffer with or without desired amount of inhi-
bitors, and 1 pg of enzyme in 10 ul of enzyme solution so that a molar 
ratio of 12 is reached for enzyme and DNA (section II.3.4.). Reaction 
was initiated by addition of enzyme. After incubation at 37° C for 10 
minutes, reactions were diluted to 1.0 ml with binding buffer and filtered 
immediately through 24 mm Schleicher and Schuell BA85 nitrocellulose 
filter disks with gentle suction (5 em of Hg, which produced a flow 
rate of approximately 4 ml/min). The filter disks were then dried and 
the radioactivity determined in toluene containing 0.4% 2,5-diaphenyloxa-
zole in a liquid scientillation counter. The amount of radioactivity 
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collected on the filter disks in the absence of any inhibitors was used 
as control. A minimum amount (-3%) of radioactivity was attributed to 
non-specific binding. 
rr.4.3. RNA Polymerase Assays 
DNA-dependent RNA polymerase activity was determined by measur-
ing the incorporation of radioactive ribouncleotide substrates into 
ribonucleic acid insoluble in trichloroacetic acid (TCA). 
Assay reaction mixtures consisting of buffer solution with or 
without inhibitors, T7 DNA, RNA polymerase solution, and radioactive 
nucleotide substrates were introduced into 12 x 75 mm disposable glass 
test tubes. The exact amount of each component was measured with Pipet-
man adjustable pipets. The test tubes and all the glasswares used in the 
experiments were pre-heated at 180° C for at least 48 hours prior to use 
to inactivate any possible contaminating ribounclease activity. Dispo-
sable plastic gloves were also worn to avoid contamination by human skin 
ribonuclease (Rovozzo, 1973). 
II.4.3.1. Assay for RNA Polymerase Activity Under the Influence of 
Anthracyclines 
In experiments designed to measure the relative inhibitory 
potency of all anthracyclines on the overall RNA synthesis in the pre-
sence of a constant amount of DNA (170 ~M DNA-P), the enzyme concen-
tration (1 pg/sample) was prepared so as to meet the desired enzyme 
to DNA ratio of 12 to 1 (Section II.3.4.). 
In these experiments, 35 pl of 2.5 times concentrated buffer A 
solution (final concentration: 0.04 M Tris-HCl, pH 7.9; 0.02 M Mgcl2 ; 
o.Ol M 2-mercaptoethanol; 1 mg/ml BSA) was mixed with 20 ~1 of 170 uM 
(final concentration) of T7 DNA and kept at 0°C. 15 ul of anthracyc-
line solution (or water when used as control) of desired concentration 
was added to the mixture and the solution was transferred to a 37° C 
bath for 5 minutes. 10 pl of enzyme solution containing 5 ~1 of 
buffer (2.5 times its final concentration), 1 ~g of commercial enzyme 
protein and deionized water was then added. After 7 minutes of pre-
incubation (i.e., after the formation of RNA polymerase-DNA binary 
complex was completed) the RNA synthesis reaction was initiated by the 
rapid addition of 10 pl solution containing 5 mM (10 times the final 
concentration) each of ATP, GTP, CTP and 3H-UTP (specific activity: 
0.02 pCi/nmol) plus 10 pl of 0.04 M Tris buffer, pH 8.0. After 90 
seconds of incubation at 37° C the reaction was terminated with 1 ml, 
freshly prepared ice-cold, 5% trichloroacetic acid solution containing 
1 M KCl and 0.05 M of sodium pyrophosphate. 
After mixing and standing in ice for 10 minutes the insoluble 
material was collected by filtration through a Watman GF/C (2.4 em) 
filter disk with gentle suction. The filter disk was washed with 20 
ml of ice cold 5% TCA solution containing 1.0 M KCl and 0.05 M Na2P2o4 
followed by 30 ml of 95% ethanol, dried overnight (or at 95° C for 5 
minutes) and counted for radioactivity in 10 ml of toluene containing 
0.4% 2,5-diphenyloxazole in a Beckman Liquid Scientillation Counter. 
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The radioactivity absorbed and retained by the filter disks and 
the radioactivity trapped within the precipitated components of the 
assay mixture was determined from the residual radioactivity of blanks 
which did not contain any enzyme. The blank values were usually less 
than 250 cpm. 
Experiments designed to measure the inhibition of ribonucleic 
acid chain initiation were conducted as described as above except that 
a nucleoside triphosphate solution containing 8-[ 32P]-ATP, CTP, GTP, 
3 
and [5,6- H]-UTP (Specific activities: l rCi/nmol and 0.02 pCi/nmol, 
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respectivity) at a concentration of 5 mM for each nucleoside Triphosphate 
(ten times the final concentration) was used. 
Special procedures for terminating the reaction and for washing 
d f . . l . 32 . . . d d were use or exper~ments ~nvo v~ng P ~ncorporat~on ~n or er to re uce 
the high background due to unincorporated radioactivity. Ractions were 
terminated by the addition of O.Sml ice-cold 0.1 M sodium pyrophosphate 
solution containing 20 mM ATP and 2 mM UTP and 0.5 ml of ice-cold 10% 
trichloracetic acid solution containing l M KCl. The insoluble material 
collected on the filter disks was soaked in 50 ml of ice-cold 5% tri-
chloracetic acid solution containing l M KCl and 0. Ol M sodium pyrophosphate 
for l hour, and further soaked in 40 ml of ice-cold 95% ethanol for 20 
minutes. The filter disks were dried as before. 
Simultaneous counting of 3H and 32P activities were performed 
in Beckman Model LS 7500 Liquid Scintillation Counter using a pre-set 
condition under which less than 2% activity spill-over between 3H and 32P 
could be detacted. 
II.4.3.2. Assay for RNA Polymerase Activity Involving Rifampicin 
Rifampicin was used in the experiments designed to measure the 
rate constants governing the initiation steps of RNA synthesis. All of 
the experiments involving rifampicin were conducted in buffer B (0.2 M 
Tris-HCl, pH 7.9; 0.01 M MgCl 2 ; 0.05 M 2-mercaptoethanol, 5 mg BSA/ml). 
II.4.3.2.l. Inactivation of RNA Polymerase-DNA Complex by Rifampicin 
In experiments designed to study the kinetics of rifampicin 
inactivation of DNA-RNA polymerase complex, the DNA-RNA polymerase 
complexes were formed as described previously (Section II.3.4.l.) in 
the presence or absence of anthracyclines. After 7 minutes of incuba-
tion at 37° C, 10 pl of rifampicin solution with a final concentration 
of 0.312 pg/ml was added. Incubation was continued for a designated 
period of time and the RNA synthesis reaction was initiated by adding 
10 pl of radioactively labeled substrates. The reaction was terminated 
90 seconds later and the product was processed as described previously 
(Section II.4.3.l.). Under these conditions, the amount of RNA formed 
should be a direct measure of the amount of active RNA polymerase bound 
to DNA complexes. The number of complexes at t = 0 is experimentally 
defined as the amount of RNA synthesis obtained in 90 seconds when both 
rifampicin and the four ribonucleoside triphosphates were added to the 
complexes at the same time. 
II.4.3.2.2. Assay for the Rate of RNA Synthesis as a Function of 
Rifampicin Concentration 
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In experiments designed to measure the rate of RNA synthesis as 
a function of rifampicin concentration, the enzyme-DNA complexes in the 
presence or absence of anthracyclines were prepared as described pre-
viously (Section II.4.3.l.). RNA synthesis was initiated by the addi-
tion of 20 pl of a substrate-rifampicin mixture (10 pl substrate, 10 pl 
rifampicin in 0.04 Tris-HCl, pH 7.9) prepared so as to give the desired 
final rifampicin concentrations. The reaction was then terminated and 
the product processed as described previously (Section II.4.3.l.). 
II.4.3.2.3. Assay for the Rate of RNA Synthesis as a Function of Pre-
incubation Time 
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In experiments designed to measure the rate of RNA synthesis as 
a function of pre-incubation time, the drug-DNA complexes were prepared 
as described previously (Section II.4.3.l.) but at 0° C. After addition 
of the desired amount of enzyme, the reaction mixture was transferred to 
a water bath at 37° c for the appropriate period of time (i.e., for 
various pre-incubation times) and RNA synthesis was initiated by the 
addition of substrate-rifampicin mixtures. The termination and product 
processing steps were identical as described previously (Section II.4.3.l.) 
II.4.3.2.4. Assay for the Rate of RNA Synthesis as a Function of Pre-
incubation Temperature 
In experiments designed to measure the rate of RNA synthesis as 
a function of pre-incubation temperature, the drug-enzyme-DNA complexes 
were prepared as described previously (Section II.4.3.l.) but at 0° c. 
Then the complexes were transferred to a water bath at different temper-
atures for pre-incubation for 7 minutes. The RNA synthesis reaction was 
initiated at 37° C and the subsequent reaction and product were treated 
as described previously (Section II.4.3.l.). 
The background values for experiments involving rifampicin were 
determined from reaction mixtures prepared identically with each ex-
periment but in the absence of the enzyme. These values were usually 
less than 750 cpm. Higher background vales (from 750 to 1000 cpm) were 
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obtained when daunomycin was present together with rifampicin. The 
reason for this higher background is not known but it may be attributable 
to interaction among rifampicin, daunomycin and the radioactive substrates. 
CHAPTER III 
EXPERIMENTAL RESULTS 
III.l. The Binding of Anthracyclines to T7 DNA 
In order to study the effects of anthracyclines on RNA synthesis, 
the binding parameters for each drug on DNA must be obtained under ionic 
and temperature conditions identical to those employed in the assays for 
RNA polymerase activities. 
Binding experiments for each anthracycline analog were conducted 
as described under Methods (Section II.4.1.). Preliminary results indi-
cated that BSA had no effect on the extent of binding and in subsequent 
measurements BSA was omitted from the buffer. In these measurements, 
the concentration of the drug was kept constant at approximately 20 pM, 
while the concentration of T7 DNA was varied. 
Typical spectrophotometric titrations of anthracyclines with DNA 
are shown in Figure 8 which demonstrates the effect of increasing amount 
of DNA on the absorption spectra of anthracyclines. Under the specified 
conditions, free daunomycin exhibits three absorption maxima at 502, 535 
and 575 nm as shown in Figure Sa. This significant change in absorption 
spectrum from that mentioned in Section I.2.7.1. is due to the presence 
of MgC1 2 • Although high concentration of Mg
2
+ was reported to release 
anthracyclines form the drug-DNA complex (Calendi et al., 1965) the 
concentrrion of MgCl 2 present in this study is significantly lower. 
Upon addition of T7 DNA, the intensity at all absorption maxima 
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Figure Sa. Visible Absorption Spectra for daunomycin-T7 DNA Complex 
Experiments were conducted with a Perkin-Elmer 320 spectrophoto-
meter. 18.8 ~M of daunomycin in binding buffer (0.04 M Tris-HCl, pH 
7.9, 0.02 M MgC1 2 , 0.01 M 2-mercaptoethanol) was mixed with increasing 
amount of T7 DNA as described in Methods (Section II.4.1.). The con-
centrations of T7 DNA are a) 0 ~M, b) 88 ~M, c) 114 ~M, d) 168 ~M, 
e) 204 pM, f) 243 ~M, g) 288 pM, h) 390 ~M. 
Measurements were carried out at 37° c. A minimum of three 
determinations of binding parameters were made for each anthracycline-
DNA combination. Each binding determination consisted a minimum of 9 
different DNA concentrations in duplicate samples. Only a portion of 
the data is shown. 
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Figure 8b. Visible Absorption Spectra for Aclacinomycin-T7 DNA Complex 
20 pM of aclacinomycin solution in binding buffer was mixed with 
increasing amount of T7 DNA as described in Figure Sa. The concentrations 
of DNA are a) 0 pM, b) 48 ~M, c) 96 pM, d) 175 pM, e) 242 pM, f) 390 pM. 
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600 
decreases and the two maxima at longer wavelength tend to disappear more 
quickly than the one at 502 nm, which became predominant at the highest 
DNA to drug ratio employed. The largest changes in absorbance were ob-
served at 535 and 575 nrn and the absorbances at these wavelengths were 
used in the calculation of binding parameters. 
Only one clear isosbestic point is observed for daunomycin. If 
there had been a DNA concentration range in which the spectra of the 
drug-DNA complex had exhibited an isosbestic point while in another DNA 
concentration range no isosbestic point had been observed, this would 
have been a clear indication of the presence of more than two spectral 
species. This is not the case for daunomycin, therefore the spectra of 
daunomycin were evaluated under the assumption that only two spectral 
species are present in the solutions; i.e.,the free drug form and the 
DNA-bound drug form. This assumption is further supported by the find-
ings that the intrinsic association constants determined from the spec-
tral changes at 535 and 575 nrn are in good agreement with one another. 
The absorption spectra for the rest of the anthracycline analogs, with 
the exception of aclacinomycin, exhibit a similar pattern. 
Figure 8b shows the absorption spectra of aclacinomycin under 
the same experimental condition. Like that of daunomycin, the inten-
sity of the absorption maximum decreases upon addition of DNA. The ab-
sorption maximum of aclacinomycin is also shifted from 515 nm at zero 
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DNA to drug ratio to 450 nm at maximal DNA to drug ratio. An isosbestic 
point is presnet at 460 nrn. As is the case with daunomycin, the presence 
of an isosbestic point indicates that only two spectral species of acla-
cinomycin are present; the DNA-bound drug and the free drug. 
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The largest changes of absorbance were obtained at 517 nm and 
therefore, absorbances at this wavelength were used in calculating the 
binding parameters for this drug. 
The values for rb (the number of drug molecules bound per DNA 
nucleotide) and If (the concentration of free drug) for each anthracycline 
analogs studied were calculated according to equations (4) and (6) re-
The association constant (k ) and the maximum number of 
app spectively. 
binding sites per DNA nucleotide (n) for each drug were obtained from 
the slopes and intercepts of Scatchard plots constructed according to 
equation (1). 
The Scatchard plots for each anthracycline studied are shown in 
Figures 9a and 9b and the calculated values of k and n for each drug 
app 
are listed in Table l. 
In Figure 9a, at lower DNA to drug ratio, the Scatchard plots 
shown deviations from the straight line and therefore, the intercept on 
the abscissa were made by extrapolations of the linear portions of the 
plots (Chambon, 1975). The deviations indicate the existence of two dis-
tinct processes of unequal strength for the binding of anthracyclines to 
DNA. At low DNA to drug ratio, the drugs are able to bind to DNA through 
electrostatic interactions at secondary binding sites in addition to the 
intercalative mode of binding which occurs at primary binding sites when 
the DNA to drug ratio is high. This interpretation is consistent with 
that of previous studies based on Calf thymus DNA (Zunino et al., 1972) 
and model building (Section I.2.7.2.). The absence of deviation for the 
aclacinomycin group of drugs in Figure 9b indicates that no significant 
amount of secondary binding is present. This observation is consistent 
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Figure 9. Scatchard Plots for Some Anthracyclines 
The Scatchard variables of rb (the number of ligands bound per 
nucleotide) and If (the molar concentration of free drug) were calculated 
from the data obtained from spectrophotometric titrations (Figure 8) ac-
cording to the method of Peacocke and Skerett, 1956. 
a) 4-demethoxydaunomycin -e-, daunomycin -•-, carminomycin -o-. 
b) aclacinomycin -e-, marcellomycin -•-, musettamycin -o-. 
The lines were drawn using the method of linear regression with 
the aid of Apple II computer. Each value represents the mean ± the 
standard deviation of three experiments in duplicate samples. 
10 
•o 
.,.. 
)( 
.05 
80 
.10 
<D 
•o ,.. 
)( 
.: .4 
.05 
81 
b 
.10 
82 
Table I 
Binding Parameters for DNA Interaction with 
Anthracyclines 
Anthracyclines n 
Group I: 
daunomycin 3.63 ± 0.21 0.070 ± 0.050 
4-demethoxydaunomycin 5.28 ± 0.36 0.070 ± 0.002 
carminomycin 1.31 ± 0.16 0.065 ± 0.001 
Group II: 
ac1acinomycin 8.92 ± 0.54 0.100 ± 0.007 
marcellomycin 6.84 ± 0.61 0.100 ± 0.005 
musettamycin 5.59 ± 0.26 0.110 ± 0.005 
Binding parameters were determined from plots of rb/If 
versus rb, where K (the apparent association constant) is the negative 
app 
slope and n (the apparent number of binding sites per nucleotide) is the 
intercept on the rb-axis of the corresponding Scatchard plot. Each 
value represents the mean ± the standard deviation. 
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with the data obtained from fluoresence quenching studies which also 
showed only one type of binding between marcellomycin and various type 
of DNA (DuVernay et al., 1979a). As mentioned previously (Section 
I.2.7.2.) any modification of the amino group would reduce the secondary 
binding. In the case of group II anthracycline, this is probably due to 
the inability of the masked amino group to either develop a positive 
charge to form secondary binding, or, even if the charge can develop, 
its effect is weakened by the presence of the di-methyl substitution. 
In any event, the secondary binding is insignificant in the binding of 
group II anthracyclines to DNA. 
In the subsequent study of the inhibition of RNA synthesis by 
anthracycline analogs it is essential to realize that the true inhi-
bitor of the RNA synthesis system is the DNA-bound form of the drug 
(Section III.3.2.). Since from the results of the binding studies 
anthracyclines may bind to DNA in two different forms; i.e., inter-
calation and secondary binding, their effect on RNA synthesis may 
become very complicated to study. Therefore in order to understand 
the mechanism of inhibition of RNA synthesis by each DNA-bound anthra-
cycline molecule in terms of intercalation alone, one has to make sure 
that intercalation is the only mode of interaction between the drug 
and DNA. This can be achieved by limiting the number of DNA-bound 
drug molecules (rb) under 0.05 per DNA nucleotide, which, according 
to the Scatchard plot, should eliminate the possibility of secondary 
binding. Under this condition, the resulting inhibitory effect of 
anthracyclines in terms of DNA binding can only be attributable to 
intercalation alone. 
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There is approximately a 3-fold decrease in the binding constants 
and the number of binding sites when the data from the present study 
are compared with that reported in the literature (Zunino et al., 1980; 
Rich et al., 1981). This apparent discrepancy may be explained by the 
presence of Mg2+, which has been reported to reduce the normal binding 
of daunomycin to DNA (DiMarco et al., 1972; Bhuyan et al., 1965). 
Based on the shapes of the Scatchard plots, the differences in 
binding constants and the number of drug molecules bound per DNA nucleo-
tide, the anthracyclines studied in this project could be categorized 
into two groups; i.e., (I) the daunomycin group, which includes daunomycin, 
4-demethoxydaunomycin and carminomycin and (II) the aclacinomycin group, 
which includes aclacinomycin, marcellomycin and musettamycin. This dis-
tinction is also correlated to the basic structure of the anthracyclines; 
i.e., those without extra sugar groups on the daunosamine (the daunomycin 
group), and those with one or more sugar residues attached to rhodosamine 
(the aclacinomycin group). 
Generally speaking, group II anthracycline molecules bind to T7 
DNA with greater affinity and more of them can bind per DNA nucleotide. 
The increase of affinities of anthracyclines to DNA has been attributed 
to the presence of C-10 subsitution and extra residues on the glycosidic 
side chain (DuVernay et al., 1979a,b) despite the fact that the amino 
group on the primary sugar residue has been masked by two bulky methyl 
groups. The effects of other substitutions (i.e., at C-1, C-11, and 
C-13) are not clear at this moment. 
Differences in binding parameters are also noted among group I 
anthracyclines. The calculated binding constants for daunomycin and 
4-demethoxydaunomycin are found to be 3.63 x 106 M-l and 5.28 x 106 M-l 
respectively. This result shows a higher DNA binding ability for 4-
demethoxydaunomycin and is in disagreement with the binding constant 
obtained previously on Calf thymus DNA (Zunino et al., 1976) which sug-
gested a stronger binding for daunomycin. However, the present result 
is consistent with the expectation based on the structural analysis that 
4-demethoxydaunomycin should have a higher affinity for DNA due to the 
absence of the bulky methoxy group on C-4 of daunomycin (see page 48). 
III.2. Assays for the Most Appropriate Conditions to be Used in Sub-
sequent Experiments 
In order to establish the assay conditions for the inhibition 
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studies, the RNA synthesis by DNA-dependent RNA polymerase as a function 
of reaction time was studied using T7 DNA as template. The amount of RNA 
synthesized was plotted against the reaction time and the results are 
shown in Figure 10. 
From Figure 10 it is evident that for the first 10 minutes, RNA 
synthesis is linear with respect to incubation time, then it slows down 
considerably and finally reaches a plateau at around 60 minutes. The rate 
of the reaction follows roughly first order kinetics as can be seen from 
the linear plot in Figure 11. A reaction time of 90 seconds was used in 
all subsequent assays to eliminate reinitiation (see Methods), and this 
reaction time falls well within the limit of 10 minutes beyond which sub-
strate depletion may occur. 
The effect of template concentration on RNA synthesis was also 
studied and the results are presented in Figure 12. The reaction seems 
to follow Michaelis-Menton kinetics and the Lineweaver-Burk plot is pre-
Figure 10. The Kinetics of RNA Synthesis 
170 pM of T7 DNA was pre-incubated at 37° C with 1 pg of RNA 
polymerase for 8 minutes. The initation was started by the addition of 
0.5 mM of 3H-labeled nucleotide substrate. The reaction was terminated 
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according to the time specified and the radioactive product was collect-
ed and processed as described in the Methods (Section II.4.3.1.). 
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Figure 11. First Order Plot of the Effect of Reaction Time on RNA 
Synthesis 
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Figure 12. The Effect of Template Concentration on RNA Synthesis. 
Various amount of T7 DNA were mixed with RNA polymerase for 
8 minutes. The reaction was then initiated by rapid addition of 5 mM 
3 
of H-labeled substrates and terminated 90 seconds later. RNA poly-
merase activity is expressed as radioactivity retained on filter papers. 
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sented in Figure 13. It is also apparent from Figure 12 that the maxi-
mum amount or incorporation of radioactivity occurs at 170 ~M of DNA-P 
when 5 mM (initial concentration) of labeled nucleotide solution is used. 
Therefore, for subsequent experiments DNA concentration of 170 ~M and an 
enzyme to DNA molar ratio of 12 were used to ensure the highest amount 
of incorporation of radioactive materials under the specific 3H-labeled 
nucleotide concentration. 
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Figure 13. Linewaver-Burk Plot of RNA Polymerase Activity as A Function 
of Template Concentration 
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III.3. The Inhibition of RNA Polymerase Activity By Anthracyclines 
III.3.1. The Relative Potency of Anthracyclines on the Overall Inhibi-
tion of RNA Synthesis 
The relative inhibitory activity of anthracyclines were studied 
by determining the level of RNA polymerase activities in the presence 
and absence of the drugs. Increasing amounts of drug were mixed with 
constant amounts of DNA, enzyme and nucleotide substrates and assayed 
for RNA polymerase activity, which was expressed as the amount of radio-
active materials incorporated after a specific reaction time. The inhi-
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bitory activity of each drug was expressed as the percent residual enzyme 
activity determined by the radioactive materials synthesized, under the 
influence of increasing amount of anthracyclines, over that in the ab-
sence of drug. 
In Figure 14, percent radioactivities are plotted vs the total 
added drug to DNA-P ratio. Clearly this ratio of drug over DNA-P does 
not provide any information as to the amount of drug that is actually 
bound to DNA. 
From Figure 14 the effectiveness of each anthracycline in the 
inhibition of the overall RNA synthesis can be obtained. The added drug 
to DNA-P ratios which cause 50% inhibition of RNA synthesis for the dif-
ferent anthracyclines are listed in Table II. 
In general, the ability of each anthracycline to inhibit RNA syn-
thesis rises sharply with increasing amounts of added drug until roughly 
a 0.1 added drug to DNA ratio is reached. Beyond this point the increase 
in inhibition slows down and finally reaches a maximum. However, even 
though the inhibitory curves for all the drugs studied have a similar 
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Figure 14. The Overall Inhibitory Effectiveness of Anthracycline Analogs 
on T7 RNA Synthesis 
Enzyme-template binary complexes were formed by mixing 1 pg of 
RNA polymerase with 170 uM of DNA in the presence of desired amount of 
daunomycin (e) , 4-demethoxydaunomycin ( 0) , carminomycin ( •), 
aclacinomycin ( t:..) , marcellomycin ( o) , and musettamycin ( • ) at 37° C, 
so that the added drug to DNA ratios were maintained within the range of 
0 to 0.4. RNA synthesis was then initiated with the addition of ribonu-
cleotide substrate (0.5 mM each of ATP, GTP, CTP and 3H-UTP, 0.02 pCi/nmol) 
and terminated 90 seconds later with 5% TCA. The acid insoluble RNA pro-
duct was collected on a filter paper and counted for radioactivity in a 
liquid scintillation counter. The amount of radioactivity obtained at 
zero drug concentration was used as 100% RNA polymerase activity. 
Each value represents the mean ± the standard deviation of six experi-
ments. 
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Table II 
Comparison of the Inhibitory Effectiveness of Some Anthracyclines towards 
RNA Synthesis 
Anthracycline 
analogs 
Group I: 
daunomycin 
Added drug/DNA ratio 
resulting in 50% inhibition 
0.078 
4-demethoxydaunomycin 0.058 
carminomycin O.llO 
Group II: 
aclacinomycin 0.030 
marcellomycin 0.033 
musettamycin 0.043 
13.3 
9.9 
18.7 
5.1 
5.6 
7.3 
shape, they may be separated into two groups according to the structure 
of the compounds mentioned before. 
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Important quantitative differences in the inhibitory behavior 
of anthracyclines are evident from Table II. For the same ratio of add-
ed drug to DNA (i.e., Ic 50 ), the aclacinomycin group is generally more 
effective (twice as effective on the average) than the daunomycin group. 
This higher effectiveness against RNA synthesis for group II anthracy-
clines is consistent with the result from in vitro studies with tumor 
cells (Crooke et al., 1977). 
Results from the binding study (Table I) show that more drug 
molecules from group II anthracyclines can bind per unit DNA than group 
I drugs. This is indicated by the smaller size of binding sites (1/n, 
with n being the number of binding sites per unit DNA) required for group 
II anthracyclines. In addition, group II drugs can bind to DNA with 
greater affinity. Since previous reports indicated that RNA synthesis 
was directly related to the amount of DNA-RNA polymerase stable complexes 
formed (Hinkle and Chamberlin, 1972 a-d), it is logical that when identical 
amount of drugs from group I and group II anthracyclines are added to a 
constant amount of DNA, more drug molecules from group II can bind to DNA 
with greater affinities and thus inhibit the formation of the DNA-RNA 
polymerase complex to a greater extent. 
The relative effectiveness of anthracyclines toward RNA synthesis 
inhibition within each group can also be evaluated in terms of their bind-
ing parameters. For example, the differences in the extent of inhibition 
between members of group I anthracyclines follow closely with their bind-
ing affinities. Specifically, in the case of 4-demethoxydaunomycin, the 
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removal of the methoxy group on C-4 increases both the binding and inhi-
bitory effectiveness of the drug. From the x-ray diffraction study of 
the crystals of the intercalated complex of daunomycin and DNA (Rich 
et al., 1981) it is evident that ring A which contains the methoxy group 
penetrates completely through the base pairs and hangs out on the other 
side into the major groove. Removal of this bulky methoxy group may aid 
the penetrating process, thereby stabilize the intercalated complex. On 
this basis one might expect that carminomycin also should be a better 
binding drug than daunomycin. However, carminomycin was found to bind 
less strongly to DNA and to inhibit RNA synthesis less than daunomycin. 
Similar results have also been obtained in the comparative study of DNA 
binding between carminomycin and adriamycin (DuVernay et al., 1980). It 
is possible that inter- or intra-molecular hydrogen bonding involving the 
C-4 hydroxyl group of carminomycin might be present which could interfere 
with the intercalation of the aglycone of this compound. 
No significant differences in either the binding effectiveness 
or the RNA synthesis inhibitory effect were found among members of group 
II anthracycline probably because no significant differences are present 
in the substitution on the aglycone of these drugs. 
In any event, there seems to be a structural-activity relation-
ship among the two groups of anthracyclines studied. Substitutions on 
C-10 and C-4' provide group II anthracyclines with better binding affi-
nities to DNA and therefore stronger inhibitory effect on overall RNA 
synthesis over that of group I drugs. Furthermore, C-4 substitutions for 
group I anthracyclines play an important role in changing anthracycline 
binding to DNA and the ability to inhibit RNA synthesis. 
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III.3.2. The Effect of DNA-Bound Anthracyclines on RNA Synthesis 
Daunomycin has been shown to inhibit RNA synthesis by reducing 
the availability of DNA template for binding RNA polymerase. This re-
duced availability is a consequence of daunomycin intercalating to DNA 
(Mizuno et al., 1975). Daunomycin has no effect on the activity of RNA 
polymerase per se (Zunino, et al., 1974). Therefore the form of the drug 
in solution which is active in the inhibition of RNA synthesis is the 
DNA-bound form, and Figure 15, which is a plot of the RNA polymerase 
activity vs DNA-bound drug concentration (i.e., rb, Section II.4.1.), is 
essential for providing information regarding differences on the inhibi-
tion of RNA synthesis by anthracycline on a molecular level. 
The corresponding rb value for each added drug to DNA ratio in 
Figure 14 was obtained using equations (1) and (2) and subsequently 
Figure 14 was converted into Figure 15. In this figure, the relative 
effectiveness of each anthracycline analog expressed in terms of DNA-bound 
concentration (rb) toward inhibition of RNA synthesis, are compared. 
The rb values for each anthracycline analog which cause 50% RNA inhibition 
are listed in Table III. 
The results in Figure 15 appear strikingly different from those 
shown in Figure 14. Specifically, on the basis of equal amount of drug 
molecules bound to T7 DNA, the relative inhibitory effectiveness of group 
I and group II anthracyclines are reversed, i.e., the members of the dauno-
mycin group are more effective in inhibiting RNA synthesis than the mem-
bers of the aclacinomycin group. This finding indicates that identical 
numbers of bom1d drug molecules per unit DNA have different inhibitory 
effects on the ability of RNA polymerase to utilize DNA as template for 
Figure 15. The Inhibiroty Effectiveness of DNA-Bound Anthracyclines 
Toward RNA synthesis 
RNA polymerase activity is plotted verses the number of drug 
molecules bound to each DNA nucleotide (rb). 
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daunomycin ( e ) ; 4-demethoxydaunomycin ( 0) ; carrninomycin ( & ) ; 
aclacinomycin (.e. ) ; marcellomycin ( o); musettamycin ( •) • 
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Table III 
Comparison of the Inhibotory Abilities of Anthracyclines based on the 
Concentration of DNA-bound Drug 
Anthracyclines 
Group I: 
daunomycin 
4-demethoxydaunomycin 
carminomycin 
Group II: 
aclacinomycin 
marcellomycin 
musettamycin 
~ at which 50% inhibition is observed 
0.015 
0.011 
0.016 
0.020 
0.022 
0.024 
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RNA synthesis. Consequently, the inhibitory effectiveness of these 
anthracyclines is determined not only by the affinity of each drug to DNA 
but may also by the specific structure of the drug molecules from each 
group of anthracyclines. 
Besides the binding of RNA polymerase to DNA, another area which 
directly affects RNA synthesis is the mechanism by which RNA polymerase 
carried out its catalytic functions. The mechanism of DNA synthesis has 
been shown to be sensitive to the structures of the intercalated anthra-
cyclines (Goodman and Lee, 1977; Section I.2.8.2.). It is likely, there-
fore, that different structures of the intercalated anthracycline analogs 
might also affect the mechanism of RNA synthesis to a different extent. 
At this point it should be noted that the concentration of anthra-
cyclines at which the inhibition of ~~A synthesis is studied (i.e., rb< 
0.035) is far less than the level for secondary binding to occur (rb > 
0.05). Therefore the inhibitory effect of the drug studied is not due 
to the result of secondary binding. 
III.3.3. _The Effect of Template Concentration on the Overall RNA 
Synthesis Inhibition By Anthracycline Analogs 
Previous studies have demonstrated that daunomycin inhibits RNA 
synthesis competitively with the template and the inhibition can be over-
come by re-addition of the template (Zunino et al., 1974). In the present 
study, RNA synthesis under the influence of anthracyclines was studied by 
determining the level of RNA polymerase activity as a function of template 
concentration in the presence and absence of a constant amount of various 
inhibitors. Inhibitor concentrations were chosen so as to cause 50% inhi-
bition of overall RNA synthesis as determined in Section III.3.1. 
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The results from two representative members of group I anthracy-
clines (daunomycin and carminomycin) and one from group II anthracyclines 
(aclacinomycin) are presented as Lineweaver-Burk plots in Figure 16a, b 
and c. The lines for the inhibited and un-inhibited reactions cross over 
on the coordinate indicating competitive inhibition for all the anthra-
cycline analogs studied. Clearly the inhibitory effects of each drug 
can be completely abolished when the concentration of DNA is in large 
excess relative to that of the inhibitor. In addition, pre-incubation 
of the drugs with RNA polymerase was found to have no effect on the 
inhibition. 
It is also apparent that the Lineweaver-Burk plots for the in-
hibited reactions deviate from linearity. This deviation is more pro-
nounced at higher drug to DNA ratios. This surprising behavior is due 
to the fact that in the presence of a constant amount of intercalators, 
the increase in DNA concentration causes a gradual decrease in rb (the 
number of DNA bound drug molecules per DNA nucleotide) as indicated by 
equation (7) (Section III.3.2.). Since the actual concentration of the 
inhibitors should be expressed in terms of r rather than [I ] , a gradual 
b 0 
decrease in rb also gradually reduces the slope of the inhibited plot in 
Figure 16, and results in curvilinearity. A similar observation has been 
reported in the study of the interactions between phenanthridines and 
DNA (Aktipis and Panayotatos, 1981). 
In any event, this result demonstrates that anthracyclines studied 
in this project competitively inhibit RNA synthesis and is consistent 
with the proposal that the inhibition of RNA synthesis by anthracycline 
is primarily due to the inactivation of the template (Zunino et al., 1974). 
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Figure 16. The Effect of Template Concentration on RNA Synthesis 
The amount of RNA synthesized was measured in the absence of 
intercalators (e), or in the presence (O) of (a) 13.3 ~M of daunomycin, 
(b) 18.7 ~M of carminomycin, and (c) 5.1 ~M of aclacinomycin. 
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III.3.4. Mechanisms of Inhibition of RNA Synthesis By Anthracycline Analogs 
The results presented in the preceding pages suggest that the 
mechanisms by which the two groups of anthracycline analogs inhibit RNA 
synthesis may be different despite the fact that they all inhibit RNA 
synthesis competitively. Previous reports on the mechanism of RNA syn-
thesis inhibition by daunomycin have suggested that daunomycin inhibits 
RNA synthesis initiation without significantly affecting elongation due 
to the relatively rapid dissociation of the drug from DNA (Schellinx et 
al., 1979). However, this conclusion is clearly in contradiction with 
a previous report in which daunomycin was found to affect the elognation 
of RNA chains (Zunino et al., 1974). Since the initiation of RNA synthe-
sis from T7 DNA by E. coli RNA polymerase has been studied thoroughly and 
the different steps in the events prior to the formation of the first 
phosphodiester bond have been elucidated (Section I.3.5.), it is of in-
terest to examine the effect (if any) of each anthracycline analog on the 
events that precede the formation of the first phosphodiester bond as well 
as its effect on chain elongation. 
III.3.4.l. The Effect of Anthracycline Analogs on the Formation of DNA-
RNA Polymerase Complex 
Conflicting results have been reported concerning the ability of 
daunomycin to inhibit the formation of DNA-RNA polymerase stable binary 
complexes which are necessary prior to the formation of the first phos-
phodiester bond (Section I.2.8.l.). In this study the effect of anthra-
cyclines on the formation of DNA-RNA polymerase binary complexes were 
examined by measuring the radioactivity retained on filter paper using a 
method devised by Jones and Berg in 1966. This method is based on the 
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observation that when a buffered solution containing DNA and RNA poly-
rnerase is subjected to filtering, only the DNA-RNA polymerase binary corn-
plexes are retained on the filter if a controlled rate of filteration is 
used. Any unassociated molecules of either free DNA or RNA polymerase 
are filtered through. 3 In the present study, the amounts of H-T7 DNA 
and RNA polymerase were kept constant while increasing amounts of various 
inhibitors were added. The experimental details are presented in the 
Methods (Section II.4.2.) 
Figure 17 shows the results of the effect of anthracyclines on 
the formation of DNA-RNA polymerase binary complexes. It is evident that 
as the amounts of inhibitors increase fewer DNA-RNA polymerase complexes 
are formed as indicated by the decreasing amount of radioactivity re-
tained on the filters. The shape of the inhibitory curves is similar for 
all the anthracycline analogs studied. However, with the aclacinornycin 
group, an almost linear relationship is noted between the effectiveness 
of the members of the group in dissociating the enzyme-DNA complex and 
drug concentration up to low concentrations of the drug. The inhibition 
of the binary complex formation by members of the daunomycin group, on 
the other hand is relatively low until an added drug to DNA ratio of 
about 0.04 is reached. Beyond this point inhibition increases fairly 
rapidly with increasing amount of added drug. However, the increase is 
not as rapid as that noted for the aclacinornycin group. 
The added drug to DNA ratio for each drug at which only 50% of 
the binary complex is formed are listed in Table IV. Comparison of the 
data in Table II and Table IV indicates that within group II anthracyclines 
the relative inhibitory effect of each drug against complex formation 
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Figure 17. The Effectiveness of Anthracyclines on the Dissociation of 
the DNA-RNA Polymerase Binary Complex: Amount of Complex Determined by 
the Nitrocellulose Filter Assay 
3 10 ~1, 170 ~M of H-T7 DNA in 80 ul binding buffer with or without 
desired amount of rifampicin or anthracyclines, was mixed with 10 pl 
(containing l ~g) of RNA polymerase. After incubating at 37° C for 10 
minutes, the mixture was diluted to 1.0 ml with binding buffer and fil-
tered through a nitrocellulose filter paper. The radioactivity collected 
on the filter is proportional to the amount of DNA-RNA polymerase binary 
complexes formed. 
Results obtained: without anthracycline but in the presence of 
rifampicin (X) ; in the presence of daunomycin ( •); 4-demethoxydauno-
mycin ( 0); carminomycin ( • ) ; aclacinomycin ( A); marcellomycin ( o ) ; 
musettamycin ( •). Each value represents the mean± the standard 
deviation of four experiments. 
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Table IV 
Effect of Anthracyclines on the Formation of 
Anthracyclines 
Group I: 
daunomycin 
the DNA-RNA Polymerase Complex 
added drug to DNA ratio 
which causes 50% inhibition 
0.096 
4-demethoxydaunomycin 0.085 
carminomycin 0.140 
Group II: 
aclacinomycin 0.035 
marcellomycin 0.035 
musettamycin 0.045 
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closely parallel that of RNA synthesis inhibition. This observation 
seems to suggest that the overall RNA synthesis inhibition by group II 
anthracyclines is a direct result of their abilities to inhibit template-
enzyme complex formation. In contrast, the RNA synthesis inhibition by 
group I anthracyclines can only be partially explained by their complex 
inhibition abilities. For example, the drug to DNA ratios for daunomycin 
which cause 50% of inhibition in RNA synthesis and enzyme-template complex 
formation are 0.078 and 0.096 respectively. Other factor must also exist 
to contribute to the total RNA synthesis inhibition abilities of group I 
anthracyclines in addition to their inhibition of the DNA-enzyme complex 
formation. 
This study also shows that rifampicin, which attacks RNA poly-
merase, does not prevent RNA polymerase from binding to T7 DNA. This is 
indicated by the fact that 100% radioactivity was recovered even in the 
presence of the highest rifampicin concentration tested (1.25 ug/ml) in 
the experiment. Other experiments (data not shown) carried out in the 
presence of rifampicin with and without RNA polymerase show that only DNA-
enzyme binary complexes are retained on the filters, DNA with or without 
rifampicin is filtered through. 
III.3.4.2. The Effect of Anthracycline Analogs on Events Prior to the 
Formation of the First Phosphodiester Bond 
As described in Figure 5, the interaction of T7 DNA and E. coli 
RNA polymerase leading to the formation of the first phosphodiester bond 
consists of three sequential events: (1) reversible, weak binding of 
RNA polymerase to T7 DNA at random sites, (2) enzyme attachment to a 
site at or near a specific promoter site to form the I complex, (3) 
transformation of the I complex to a highly stable RS complex, from 
which a new complex (the OP complex) can be formed with the formation 
of the first phosphodiester bond. 
In the following experiments, the rates of each of these two 
complex transformations were studied under the influence of anthracy-
cline analogs. 
III.3.4.2.l. The Rate of RS to OP Complex Transformation 
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The antibiotic rifampicin, which has been found to inhibit RNA 
synthesis initiation without affecting elongation (Mangel and Chamberlin, 
l974c), is used in the assay for studying the rate of RS to OP complex 
transformation. In addition, rifampicin does not block the formation 
of RS complex, and does not increase the rate of dissociation of this 
complex (Section III.3.4.l.). In fact, the ribonucleoside triphosphate 
substrates are in competition with rifampicin so that once the first 
phosphodiester bond is formed, the RS complex transforms into OP complex 
and becomes insensitive to rifampicin (Mangel and Chamberlin, l974c). 
The rate of rifampicin attack on the highly stable T7 DNA-RNA 
polymerase holoenzyme complex (RS complex) has been shown to obey sec-
ond order kinetics (Hinkle et al., l972d). Therefore, if RNA polymerase-
T7 DNA binary complexes are formed in the presence of anthracyclines and 
then challenged simultaneously with a mixture of rifampicin and the four 
ribonucleoside triphosphates, two competing reactions (equations 7 and 8 
below) would take place: 
(l) Inactivation by rifampicin: 
C + R _______ k_2 ______ ~~ cr (7) 
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(2) RNA chain initiation: 
C + nXTP k* C* (8) 
In these equations C represents the concentration of RNA polymerase 
holoenzyme-T7 DNA binary complex: r C represents the concentration of the 
binary complexes inactivated by rifampicin and consequently unable to 
initiate a RNA chain; C* represents the binary complexes which have 
initiated an RNA chain and are therefore insensitive to rifampicin; 
k 2 is the second order rate constant for rifampicin attack on RNA poly-
merase-T7 complexes, and k* is an apparent first order rate constant for 
RNA chain initiation at a particular concentration of ribouncleoside 
triphosphates. 
With the assumptions that the binding of rifampicin to holoenzyme 
in the binary complex is irreversible; that RNA chain initiation by the 
binary complexes is irreversible and that during the assay, concentration 
of rifampicin and the ribonucleoside triphosphates remain constant, and 
with the use of the conservation equation: 
c 
0 
(9) 
(where C is the concentration of binary complexes at t = 0,) the follow-
a 
ing relationship can be derived from equations (7) to (9): 
[R] 
(10) 
C* k* 
The second order rate constant for rifampicin attack on holoenzyme-
3 -1 -1 
T7 DNA complexes (k 2 ) is 3.5 x 10 M S (Hinkle et al., 1972d); thus, 
only an assay for measuring C and C* is required to determine the apparent 
0 
119 
first order rate constant for RNA chain initiation (k*). With this assay, 
c is experimentally defined as the amount of RNA synthesized in 90 seconds 
0 
(Second II.4.3.2.l.) in the absence of rifampicin, and C* is the amount of 
RNA synthesized under identical conditions but in the presence of rifam-
picin. 
To calculate the rate of RNA chain initiation, equation (10) can 
be transposed utilized equation (9) to yield equation (11), 
---------- + 1 (11) 
C* k* 
where C /C* represents the reciprocal of % RNA polymerase activity. At 
0 
various concentrations of rifampicin, a graph of the reciprocal of % RNA 
polymerase activity vs the rifampicin concentration should result in a 
straight line with a characteristic slope. The slope should be equal to 
the rate of the second-order rate constant of rifampicin attack on the 
binary complex (RS) over the rate constant of the transformation of the 
RS complex to the rifampicin-insensitive ternary complex (OP), or k 2/k*. 
In order to study the effect of anthracycline analogs on the 
rate of RS to OP complex transformation, identical assays can be per-
formed in the presence and absence of anthracyclines. If anthracyclines 
change the rate of RNA synthesis initiation (i.e., the transformation of 
RS to OP complex) , the slope of the C /C* vs [R] plot should be different 
0 
assuming that the rifampicin attack on RNA polymerase is not affected by 
the presence of the intercalating anthracyclines. 
Since the rate of rifampicin attack on the RNA polymerase in RS 
complex, k2 , is crucial in the determination of the rate of RNA chain 
initiation, it must be assumed that k 2 is not affected by the presence 
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of anthracyclines in order to use the rifampicin technique in the study 
of the effect of anthracycline analogs on therateof RS to OP complex 
transformation. 
In ascertaining that anthracyclines have no effect on k2 , 4-
demethoxydaunomycin and aclacinomycin were chosen to represent group I 
and group II anthracyclines respectively. Daunomycin was not chosen for 
these experiments because it appears to interact with rifampicin, forming 
a non-specific complex which is responsible for retaining radioactive 
material on the filters thus giving erroneously high counts. 
The assays used for determining the rate constants of rifampicin 
inactivation of the RS complex in the presence and absence of the two 
anthracycline analogs are described in the Methods (Section II.4.3.2.1.). 
The results are presented in Figure lBa, b and c. 
Under the assays conditions, where rifampicin is present in great 
excess over RNA polymerase (over 10 fold), the kinetics for inactivation 
of the enzyme in the binary complex by rifampicin are pseudo first-order, 
as indicated by the first order rate plot in Figure 18. In other words, 
although the binding of rifampicin to RNA polymerase is a second-order 
reaction, under conditions where the concentration of unbound antibiotic 
can be considered constant during the reaction kobs = k2 x [rifampicin], 
where k b is the apparent rate constant for the binding of rifampicin 
0 s 
to RNA polymerase and k2 is the true second-order rate constant for the 
reaction. 
In the presence of 4-demethoxydaunomycin and aclacinomycin, RNA 
polymerase in the enzyme-DNA binary complex has a half-life of approxi-
mately 3 minutes. This half-life time is nearly identical with that 
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Figure 18. Kinetics of Inactivation of RNA Polymerase-T7 DNA Complex 
by Rifampicin at 37° C 
Enzyme-template binary complexes were formed by adding 1 ~g of 
RNA polymerase in 10 pl of enzyme solution (Section II.4.3.) to a mixture 
of 35 pl of buffer, 20 pl of DNA (170 pM) and 15 pl of H20 or anthra-
cycline solution. After 7 minutes of incubation, 10 pl of H20 with or 
without 0.38 pM of rifampicin was added. Incubation was continued for 
the indicated time intervals, then RNA synthesis was initiated by the 
3 
addition of 10 pl of 0.5 mM each of GTP, ATP, CTP and H-labeled UTP. 
The reaction was terminated 90 seconds later and the acid-insoluble 
radioactivity was determined. 
a) Incubation in rifampicin only; b) incubation in 9.9 pM of 
4-demethoxydaunomycin; c) incubation in 5.1 pM of aclacinomycin. 
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obtained in the absence of anthracyclines and is in good agreement with 
that reported by Hinkle under comparable conditions (Hinkle and Chamber-
lin, l972d). This identical half-life for RNA polymerase under the in-
fluence of various anthracyclines indicates that the rate constant of 
rifampicin attack on the enzyme in the RS complex is not affected by 
either group I or group II anthracyclines. 
The effect of different anthracycline analogs on the rate of RS 
to OP complex transformation are shown in Figure l9a, and b. For these 
experiments the concentrations of anthracyclines were chosen so as to 
cause 50% inhibition of RNA synthesis as determined in Section III.3.l. 
From the comparison of the slopes of the plots of enzyme activi-
ty vs rifampicin concentration, it is evident that group II anthracyclines 
show a striking difference in the way they affect the RS to OP transfer-
mation as compared to group II anthracyclines. Specifically, group II 
anthracyclines exhibit basically identical slopes with the slopes ob-
tained in their absence. Since k 2 is not affected by the presence of 
these drugs (Figure 18), this result indicates that the presence of 
type II anthracyclines has no effect on the rate constant of RNA poly-
merase molecules which proceed from the RS complex to form the first 
phosphodiester bond. A similar conclusion has been drawn in a previous 
study about the effect of Ethidium Bromide on the rate of RS to OP trans-
formation (Aktipis and Panayotatos, 1977). 
In contrast, group I anthracyclines produce an increase in the 
k /k* (the slope) as compared to reactions in the absence of these drugs. 2 
Since these drugs do not affect k2 (Figure 18), it is clear that they 
inhibit the rate of RS to OP complex transformation. Other inhibitors 
Figure 19. The Effect of Anthracycline Analogs on the Rate of RNA 
Synthesis Initiation 
The rate of RNA chain initiation was measured as described in 
Section II.4.3.2.2. The DNA and RNA polymerase binary complexes were 
incubated in the absence (e) and presence of anthracycline analogs at 
37° C ( • , daunomycin; ~ , 4-demethoxydaunomycin; o , carminomycin; 
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0, aclacinomycin; •, marcellomycin; X, musettamycin). RNA synthesis 
was initiated with the subsequent simultaneous addition of rifampicin 
and ribonucleotide substrates. The reaction products were treated as 
described in Section II.4.3. 
The slope in this figure represents the ratio of the rate of 
rifampicin attack on the RS complexes to the rate of RNA chain initiation, 
k2/k*. 
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which interfere with the RS to OP transformation do not appear to have 
been reported in the literature. 
III.3.4.2.2. The Rate of I to RS Complex Transformation 
Evidence has been presented (Mangel and Chamberlin, 1974a) that 
RNA polymerase molecules bind to T7 DNA at or near the T7 early promoter 
region in a conformation from which rapid RNA chain initiation is not 
possible. Enzyme molecules in this state (I complex) are in equilibrium 
with enzyme molecules in the RS conformation from which rapid RNA chain 
initiation can take place. This equilibrium is temperature dependent; 
formation of I complex is favored at low temperatures (lower than 10° C). 
The isolation of I complex has lead to the conclusion that all E. coli 
RNA polymerase molecules bind initially to T7 early promoter sites in 
the I conformation in which the DNA helix remains in a double helical 
state. The enzyme molecules then carry out melting functions to separate 
the strands and form the RS complex allowing enzyme the access to the 
base pairing residues of the DNA template. Therefore, this I to RS 
complex transformation is an another essential step prior to the actual 
initiation of an RNA chain. This tranformation in the presence of anthra-
cyclines was studied in the following manner. 
The effect of anthracycline analogs on the rate of I to RS com-
plex transformation is shown in Figure 20 in which % RNA polymerase acti-
vity is plotted as a function of pre-incubation time of the I complex in 
the presence and absence of rifampicin. RNA polymerase % activity was 
determined by dividing the radioactivity recovered either in the presence 
of rifampicin or in the presence of both rifampicin and anthracyclines 
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Figure 20. The Effect of Anthracycline Analogs on the Rate of Transfor-
mation of I to RS Complexes 
Binary Complexes between T7 DNA and RNA polymerase were formed 
at 0° C in the absence ( 0) and presence ( ~) of anthracyclines. The 
reaction mixture was brought up to 37° C for the indicated pre-incubation 
times before the addition of radioactive nucleotide substrate with or 
without rifampicin. The reaction was terminated 90 seconds later and 
the product was processed as described in Section II.4.3. 
The results are expressed as % RNA polymerase activity. This is 
the ratio of RNA synthesized in the presence of rifampicin (0.156 ~g/ml) 
only ( 0), or in the presence of both rifampicin and anthracycline ( ~), 
over that when no rifampicin is present. 
a) In the presence of 13.3 ~M of daunomycin; b) in the presence 
of 9.9 ~M of 4-demethoxydaunomycin; c) in the presence of 5.1 ~M of 
aclacinomycin. 
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with corresponding controls obtained in the absence of rifampicin. 
I complex was formed by incubating RNA polymerase with T7 DNA 
at 0° C under low salt condition either in the presence or the absence 
of anthracyclines. Daunomycin and 4-demethoxydaunomycin were chosen to 
represent group I anthracyclines while aclacinomycin was chosen to 
represent group II anthracyclines. 
As can be seen from Figure 20, for the first 60 seconds the 
amount of I complex which can be transformed into RS complex and escape 
the attack of rifampicin increases rapidly as the pre-incubation time 
increases. Beyond this initial surge, the increase of radioactivity in-
corporated slows down rapidly and reaches a plateau at around 3 minutes. 
The half-life time for the I complex in the presence and absence 
of anthracyclines can be obtained by plotting the percent of RNA poly-
merase activity at infinite pre-incubation time (too) minus the RNA 
polymerase activity at time (t) on a logarithmic scale against pre-
incubation time. The results are presented in Figure 21 which shows sim-
ilar half-lives for all the anthracyclines tested, indicating that an-
thracyclines exert no significant effect on the rate of I to RS complex 
transformation. 
III.3.4.2.3. The Effect of Anthracyclines on the Transition Temperature 
of I to RS Complex Transformation 
It has been reported that the equilibrium between the I and RS 
complexes is altered by temperature in a manner characteristic of a high-
ly cooperative process (Mangel and Chamberlin, 1974a). An enthalpy of 57 
Kcal per mole has been calculated for the formation of RS complex with 
T7 DNA and a transition temperature of 18° C has been determined. 
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Figure 21. Half-life of the Transformation of the I to RS Complex 
Binary complexes between T7 DNA and RNA polymerase were formed 
at oo C in the absence ( 0 ) and presence of 13.3 pM of daunomycin ( ~ ) ; 
9.9 pM of 4-demethoxydaunomycin ( •), and 5.1 pM of aclacinomycin( 0 
respectively. The reaction mixture was then brought to 37° C for the 
indicated pre-incubation times before initiation. The reaction was stop-
ped 90 seconds later and the product was processed as described in 
Section II. 4. 3. 
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If the rate of I to RS complex transformation is indeed not 
altered by the presence of anthracyclines as concluded from previous 
experiments, then the temperature dependency of the rate constant should 
not be affected by the drugs either. This temperature dependency could 
be studied by determining the transition temperatures of I to RS complex 
transformation in the presence of anthracycline analogs. 
In this experiment, a constant amount of T7 DNA was mixed at 0° C 
with RNA polymerase in the presence and absence of daunomycin and acla-
cinomycin, representing group I and II anthracyclines respectively. The 
I complexes formed were then pre-incubated at various temperatures for 7 
minutes before being challenged with rifampicin and substrates at 37° C. 
The results are presented in Figure 22 in which the % RNA polymerase 
activity in the presence and absence of each anthracycline is plotted vs 
pre-incubation temperatures. As expected, the transition temperature of 
approximately 18° C remains unchanged regardless of whether or not inter-
calators are present. This transition temperature is in close agreement 
with that reported previously by Mangel (Mangel and Chamberlin, l974a). 
The nearly identical transition temperatures irregardless of the presence 
or absence of anthracyclines provides an independent confirmation of the 
previous conclusion that anthracyclines have little effect on I to RS 
complex transformation. 
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Figure 22. The Effect of Anthracycline Analogs on the Transition Temper-
ature of I to RS Complex Transformation 
Binary complexes were formed between T7 DNA and RNA polymerase 
at various temperatures in the absence or presence of anthracyclines 
representing each group. The reaction mixture was then incubated at the 
indicated temperatures for 7 minutes before initiation at 37° C. The 
results are expressed as % RNA polymerase activity which is the ratio of 
the amount of RNA synthesized in the absence of anthracycline ( e ) but 
in presence of rifampicin over that in the absence of both anthracycline 
and rifampicin. The same experiment was repeated in the presence of 
daunomycin (13.3 ~M, 0) and aclacinomycin (5.1 ~M, • ). 
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III.3.4.3. Comparison of the overall RNA synthesis inhibition and the 
inhibition of RNA chain initiation by anthracyclines 
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The inhibitory effectiveness of daunomycin and aclacinomycin to-
wards RNA chain initiation was also examined by assaying the simultaneous 
0 0 f 32 d 3 ( t 0 II 4 3 1 ) 1ncorporat1on o P-ATP an H-UTP Sec 1on . . . . . The amount of 
l- 34?-ATP incorporated indicates the number of RNA chains that can be 
initated in the presence of the drugs while the amount of 3H incorporated 
measures the rate of overall RNA synthesis. In Figure 23 the amount of 
RNA synthesized in terms of the RNA polymerase activity is plotted 
versus the added drug to DNA ratio for daunomycin and aclacinomycin. 
It may be noted that the overall inhibition of RNA synthesis by 
daunomycin is much stronger than the inhibition of the number of RNA 
chains that can be initiated. Since l-32P incorporation measures the 
events of RNA initiation up to the formation of the first phosphodiester 
bond, the difference seen between 32 P and 3 H incorporation can only be 
attributed to the subsequent inhibition of RNA chain elongation. There-
fore at drug to DNA ratio of 0.175 at least 17% of the overall inhibition 
of RNA synthesis by daunomycin is due to the inhibitory effect of the 
drug on chain elongation. Aclacinomycin, on the other hand, does not 
affect chain elongation as indicated by the fact that the inhibition of 
the overall RNA synthesis coincides with the inhibition of the chain ini-
tiation. 
The data obtained from the filter binding assay (which measures 
the amount of RNA polymerase-DNA complex formed in the presence of anthra-
32 d 3 0 0 d 0 cyclines) and the data of P an H 1ncorporat1on are expresse 1n terms 
of rb (the number of drug molecules bound per DNA phosphate) a shown in 
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Figure 23. Inhibition of RNA synthesis by daunomycin and aclacinomycin 
assayed by the simultaneous incorporation of 32 P-ATP and 3H-UTP 
RNA polymerase and T7 DNA complexes were formed at 37° C in the 
presence of various amountsof daunomycin and aclacinomycin. RNA syn-
thesis was then initiated by the rapid addition of nucleoside triphos-
32 3 
phate mixture containing r- P-ATP, CTP, GTP and 5,6- H-UTP (specific 
activities: 1 ~Ci/nmol and 0.02 pCi/nmol, respectively) at a concen-
tration of 5 mM for each nucleoside triphosphate. 
The amount of RNA synthesized in the presence of daunomycin in 
terms of 3H (e) or 32P ( 0) incorporation, or in the presence of acla-
cinomycin in terms of 3H (A) or 32 P ( 6) incorporation, is expressed 
as% RNApolymerase activity versus the added drug to DNA ratio. 
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Figure 24. These data indicate that under the influence of aclacinomycin 
the level of RNA polymerase-DNA complex formation, the level of overall 
RNA synthesis and the level of RNA chain initiation all closely follow 
each other. This however is not the case for daunomycin. It is clear 
that the inhibitory effect of aclacinomycin on RNA synthesis can be 
totally explained by its effect on the binding of the enzyme to DNA. No 
other step in the RNA synthesis process is affected by this drug. For 
daunomycin, the situation is more complicated. At an rb of 0.015 a 13% 
difference between the inhibition of the formation of the complex and the 
inhibition of the RNA chains is noted. This effect is attributed to 
daunomycin inhibition of the RS to OP complex transformation, i.e., inhi-
bition of the rate of the formation of the first phosphodiester bond. 
However, there is also an additional 17% difference between the inhibi-
tion of the overall RNA synthesis and the inhibition of the initiation of 
the RNA chains. This difference can only be attributed to the inhibition 
of RNA chain elongation. 
The overall inhibition of RNA synthesis by daunomycin may be divi-
ded into two main categories; 1) the inhibition of enzyme-DNA complex 
formation and 2) the inhibition of the rate of RNA synthesis which in-
cludes the inhibition of RS to OP complex transformation and elongation. 
The relative amount of inhibition of the rate of RNA synthesis attribu-
table to either the inhibition of RS to OP complex transformation or the 
inhibition of chain elongation is dependent on the concentration of dauno-
mycin. At rb = 0.009, 17% of the rate inhibition is due to the inhibition 
of RS to OP complex transformation while 83% is due to inhibition of 
elongation. At rb = 0.013, 27% and 73% of rate inhibition is due to in-
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Figure 24. Compositeplotof% RNA polymerase activity and% of I 
complex formation in the presence of daunomycin and aclacinomycin 
The% RNApolymerase activity in the presence of daunomycin in 
terms of 3H ( • ) or 32 P ( 0 ) incorporation and the % of enzyme-DNA 
complex formation ( O ) are plotted versus rb (the number of drug mole-
cules bound per unit DNA). The same plots are also constructed for 
aclacinomycin in terms of 3H ( • ) , 32P ( ~ ) incorporation and the % 
of enzyme-DNA complex formation ( • ). 
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hibition of RS to OP complex transformation and elongation, respectively. 
The inhibition of RS to OP complex transformation relative to the inhi-
bition of elongation increases further at even higher rb values (i.e., 
at rb = 0.015 which causes 43% and 57% for inhibition of complex trans-
formation and elongation, respectively). This observation indicates that 
at high daunomycin concentration, the inhibition of RS to OP complex 
transformation becomes more significant. A similar effect may have also 
been noted previously from the studies of Miracil D (Bodoni, 1978). In 
this report Miracil D was found to inhibit the initiation at high rb 
values in addition to its inhibitory effect on elongation but at lower 
rb values Miracil D was found to inhibit only elongation. 
CHAPTER IV 
DISCUSSION 
The anthracycline analogs examined in this study can be divided 
into two groups according to their structural characteristics. The struc-
tural differences between anthracyclines in group I (daunomycin, 4-deme-
thoxydaunomycin and carminomycin) and group II (aclacinomycin, marcello-
mycin and musettamycin) anthracyclines are shown in Figure 1 and are dis-
cussed in Section I.4. The major differences relate to the nature of the 
substituents at C-10 and C-13 of the aglycone and the nature of the gly-
cosidic side chain. These structural differences have been shown in 
this study to influence not only the binding affinities of these drugs 
to DNA but also the mechanism by which they inhibit RNA synthesis in 
vitro. 
RNA synthesis was studied at an RNA polymerase to DNA molar ratio 
of 12 which ensured that only the major promoter sites on DNA template 
were utilized (Figure 10, Section III.2.). Under this condition, both 
daunomycin and aclacinomycin were found to inhibit the in vitro DNA-
dependent RNA polymerase activity competitively (Fig. 16, Section III.3.2.) 
at DNA concentration which corresponded to maximum incorporation of radio-
active substrate (Fig. 12, Section III.2.). This competitive mode of 
inhibition of RNA polymerase by anthracyclines is consistent with the 
proposal (Section I.2.8.1.) that the inhibition of RNA polymerase activi-
ty by anthracyclines is primarily due to the inactivation of the DNA tern-
plate. This conclusion is also supported by the observation that pre-
incubation of RNA polymerase with the inhibitors has no effect on the 
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level of RNA synthesis (Section III.3.2.). 
It has been proposed that the inhibition of RNA polymerase by 
anthracyclines results from intercalation (Section I.2.7.2.). However, 
the precise mechanism by which the intercalators inhibit the template 
activity of DNA remains unclear. In this investigation, it has been 
shown that all the anthracycline analogs examined reduce substantially 
the binding of RNA polymerase at the major promoter sites of T7 DNA 
(Fig. 17, Section III.3.4.1.). It is likely that RNA polymerase is pre-
vented from binding to the template because the enzyme binding sites are 
already occupied by the intercalators, or due to steric hindrance by the 
molecules of the bound drug in the vicinity of the enzyme binding site. 
There are substantial differences in the effectiveness of group I 
and II anthracyclines as inhibitors for the formation of the enzyme-
template binary complex. Specifically, the drug to DNA ratios which 
causes 50% reduction in the formation of the enzyme-template binary com-
plex are approximately 0.09 and 0.04 for group I and II anthracyclines 
respectively (Table IV, Section 3.4.1.), indicating that group II drugs 
are at least twice as effective in inhibiting the formation of the enzyme-
template binary complex than group I drugs. 
The differences in the binding abilities between group I and II 
anthracyclines to DNA have been attributed to several major structural 
differences between these drugs. Specifically, the additional sugar 
residues on the glycosidic side chain and the presence of a C-10 car-
bomethoxy substituent in group II anthracyclines increases the binding 
affinities of anthracyclines to DNA (DuVernay et al., 1979a), while the 
presence of a substituted amino group on the primary sugar significantly 
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reduces binding (DuVernay et al., 1979b). The enhanced binding of group 
II anthracyclines to DNA, in terms of both the association constant and 
the number of binding sites per unit DNA, is evident under the conditions 
employed in the present study (Table I, Section III.l.). It appears that 
both the carbomethoxy residue and the additional sugar residue of group 
II anthracyclines are involved in increasing the stability of the inter-
calated complex to an extent which compensates for the loss of binding 
due to the presence of substituted amino groups. It is likely that the 
carbomethoxy component and the additional sugar residues offer greater 
opportunity for additional hydrogen bonding and better Vander Waals inter-
actions between the intercalators and the DNA template. However, group II 
anthracyclines also lack a carbonyl group at position C-13 which has been 
claimed to be involved in a hydrogen bonding with DNA to further stabi-
lize the intercalated complex (Section I.2.7.3.). Lack of this hydrogen 
bond may seriously compromise the stability of the complex formed by 
group II anthracyclines. This may explain the observation that when the 
ability to bind DNA and prevent the formation of enzyme-DNA complex is 
compared between daunomycin (group I) and aclacinomycin (group II) in 
terms of rb (the number of drug molecules bound per unit DNA), group I 
drugs become just as effective as group II drugs (Fig. 24, Section, III. 
3.4.3.). This observation indicates that each DNA-bound molecule of 
daunomycin is just as effective in preventing the formation of complex 
as is each molecule of aclacinomycin. The difference between the two 
drugs seen in terms of their added drug to DNA ratio may be attributed 
to the fact that the number of binding sites for group II drugs are 
greater than that for group I drugs. Therefore, when the same concentra-
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tion of daunomycin or aclacinomycin is added to the DNA more molecules 
of group II anthracyclines can bind to DNA and thus prevent the formation 
of enzyme-DNA complex to a higher extent. The differences in the binding 
constants of these anthracyclines to DNA seem to play a minor role in 
determining their effectiveness as inhibitors toward the formation of the 
enzyme-DNA complex. 
Since the binding of RNA polymerase to DNA at major promoter sites 
leads to the formation of an enzyme-template binary complex which is a 
necessary for the subsequent events in specific RNA synthesis initiation 
(Section I.3.4.), it may be proposed that the reduction in the formation 
of this enzyme-template binary complex by anthracyclines accounts for 
the resulting inhibition of RNA synthesis. However, when the effective-
ness of anthracyclines in reducing enzyme-template complex formation 
(Fig. 17 and Table IV, Section III.3.4.1.) is compared with the effec-
tiveness of these drugs as inhibitors of RNA synthesis (Fig. 14 and 
Table II, Section III.l.), some interesting discrepancies become apparent. 
While it is clear that the extent of enzyme-template complex inhibition 
by group II anthracyclines parallels the extent of RNA synthesis inhi-
bition, i.e., the drug to DNA ratio which causes 50% of inhibition in 
both the process of complex formation as well as RNA synthesis is similar 
for group II antibiotics (e.g., 0.033 for marcellomycin), this is not the 
case for group I anthracyclines. From the same comparison for group I 
drugs it becomes evident that a higher drug concentration is required 
(for example, 4-demethoxydaunomycin at a ratio of 0.058 prevents the 
synthesis of RNA by 50% whereas in order to prevent the formation of the 
binary enzyme-template complex to the same extent 4-demethoxydaunomycin 
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must be present at a much higher ratio, i.e., 0.085) so that the for-
mation of binary complex can be inhibited to the same extent as the 
synthesis of RNA. In other words, RNA synthesis inhibition by group I 
anthracyclines can be explained only partially by the effect of these 
drugs on binary complex formation. Therefore the differential inhibitory 
capacity of the anthracyclines is not simply the result of their different 
affinities for DNA for group I anthracyclines. Other factors must also 
be involved in the mechanism of the inhibition of RNA synthesis. 
The study of interactions between DNA and drugs is not a simple 
task because DNA contains multiple binding sites for drug molecules (Table 
I, Section III.l.). The structures of the drugs also influence the 
strength of the binding (Table I). Since anthracyclines inhibit the 
synthesis of RNA by reducing the availability of DNA template sites for 
the binding of RNA polymerase, the form of the drug in solutions which 
behaves as an inhibitor is the DNA-bound form. The appropriate means of 
expressing quantitatively the concentration of DNA-bound drug is in terms 
of the ratio of drug molecules bound per DNA nucleotide, (rb) (Section 
III.3.3.). Since rb does not depend linearly on the total drug concen-
tration (Section III.3.3.), the availability of rb values is essential 
for the comparative study of the inhibitory effectiveness of anthracy-
cline analogs which have different affinities toward the DNA template. 
When the dependence of RNA polymerase activity was determined 
as a function of rb for each drug (Fig. 15, Section III.3.3.), a different 
picture for the relative effectiveness of the various anthracyclines 
studied became apparent. Specifically, group I anthracyclines are more 
effective inhibitors of RNA synthesis than group II drugs. These results 
also indicate that identical numbers of bound inhibitor molecules per 
molecule of DNA have different inhibitory effects on the activity of 
RNA polymerase. Consequently, the inhibitory effectiveness of group I 
anthracyclines is determined not only by the affinity of each compound 
towards DNA, as in the case with group II anthracyclines, but also by 
the specific structures of the intercalated molecules. 
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What is the basis for the differential inhibitory effect on RNA 
synthesis between group I and II anthracyclines? An answer to this 
question can be found by comparing the rates of transformation of the 
binary enzyme-DNA complex during the events leading to the initiation of 
RNA synthesis in the presence of group I and II inhibitors. 
E. coli RNA polymerase molecules bind to T7 DNA at or near pro-
moter sites to form I complex (Section I.3.4.). I complexes are then 
transformed through an energy requiring step involving the separation 
of the double helical strands of DNA to form RS complexes. In the pre-
sence of nucleoside triphosphate substrates, the RS complexes can be 
transformed to OP complexes with the formation of the first phosphodiester 
bond. The rates of I to RS and RS to OP transformation can be measured 
(Section III.3.4.2.). 
In the present study the effect of anthracyclines on the rates of 
these transformations was examined. The results clearly indicate that 
in the presence of group II anthracyclines, the number of RS complexes 
is reduced (Fig. 17, Section III.3.4.1.) but the rate of RS to OP complex 
transformation is not affected (Fig. 19, Section III.3.4.2.1.). The 
reduced number of RS complex could be the consequence of either a reduced 
number of I complexes or a reduced rate of I to RS transformation, or it 
may be the result of both. Since I complexes in the process of their 
transformation to RS complexes are not affected by the presence of 
group II anthracyclines (Fig. 20-22, Section III.3.4.2.2.), the only 
explanation for the reduced number of RS complexes that can be offered 
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is that the number of I complexes is substantially reduced by group II 
anthracyclines. This observation leads to the conclusion that inhibition 
of RNA synthesis by group II anthracyclines is entirely due to the effect 
of these drugs in preventing the formation of enzyme-template binary com-
plex. This conclusion is also consistent with the findings (Fig. 24, 
Section III.3.4.3.) that the extent of enzyme-DNA complex inhibition, 
the extent of inhibition of RNA initiation (RS to OP complex transforma-
tion) and the extent of inhibition of overall RNA synthesis are all 
identical in the presence of aclacinomycin (a group II anthracycline). 
On the contrary, group I anthracyclines reduce the number of RS 
complexes (Fig. 17, Section III.3.4.1.) as well as the rate of RS to OP 
transformation (Fig. 19, Section III.3.4.2.l.) but they do not affect 
the rate of I toRS transformation (Fig. 20-22, Section III.3.4.2.2-3.). 
By the same analogy described above for group II drugs, it seems that 
group I anthracyclines also reduce the number of I complexes. In addi-
tion, however, once I complexes have proceeded to become RS complexes, 
the subsequent RS to OP transformation is also affected by group I anthra-
cyclines, probably due to the interference of these drugs with the forma-
tion of the first phosphodiester bond. (At this point it should be noted 
that the effect of daunomycin on RS to OP complex transformation is not 
an artifact due to its inhibition on chain elongation. Miracil D, which 
has been shown to be a chain elongation inhibitor at low drug concentra-
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tion, has no effect on the rate of RS to OP transformation when measured 
in an identical assay utilizing rifampicin (data not shown). 
Finally, a comparison of theratesof initiation of RNA chains 
and overall RNA synthesis (Fig. 23, Section III.3.4.3.) shows that 
daunomycin (group I anthracycline) also inhibits the elongation of RNA 
chains. Furthermore, the relative amount of RNA synthesis inhibition by 
daunomycin due to either the inhibition of the RS to OP complex transfor-
mation or of the elongation of RNA chains is dependent on the concentra-
tion of the drug (Section III.3.4.3.). At high drug concentration the 
inhibition of RS to OP transformation becomes more significant. These 
additional steps of inhibition explain the observation cited previously 
that inhibition of the enzyme-template complex by group I anthracyclines 
can only partially account for the inhibition of RNA synthesis. 
Numerous attempts have been made (Section I.4.) to establish a 
relationship between the structures of anthracycline analogs and their 
properties. It is quite apparent from the results of this study that 
the structural differences between group I and II anthracyclin~s contri-
bute to the differences in the tendencies of the members of the two 
groups to bind DNA. The latter property directly affects the effective-
ness of anthracyclines as inhibitors of RNA synthesis. More specifically, 
the structural differences among these drugs appears to affect the mech-
anism of initiation of RNA synthesis, i.e., the various members of group 
I anthracyclines affect RS to OP transformation and elongation, while 
group II anthracyclines do not. 
It has been established that the amino group on the sugar residue 
of daunomycin is positively charged at neutral pH. This charged amino 
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group plays an important role in the formation of a stable intercalated 
complex between daunomycin and DNA (DiMarco. et al., 1971) by having 
electrostatic interaction with the negatively charged phosphate backbone 
of DNA. Alteration of this amino group (either by elimination or sub-
stitution) may result in a significant reduction of intercalation. It 
has also been proposed that at very high drug concentration, this posi-
tively charged amino group is responsible for the secondary binding of 
the drug with the phosphate backbone of the DNA helix. In this case, 
drug molecules, rather than intercalating into DNA, are located on the 
outside of the double helix (Section I.2.7.2.). This secondary binding 
takes place presumably after the intercalation sites have been saturated 
at high drug concentration. 
In the present study, the potential for secondary binding for 
group I anthracyclines is evident from the Scatchard plots (Fig. 9a, 
Section III.l.) at very high drug concentrations. This finding is con-
sistent with the presence of an unsubstituted amino group on the primary 
sugar residue. Group II anthracyclines carry a substituted amino group 
and do not form secondary binding as is evident from the linearity of 
the corresponding Scatchard plots (Fig. 9b, Section III.l.). However, 
since the assays for the inhibition of RNA synthesis by anthracyclines 
were carried out at drug concentrations far below (below rb = 0.035, Fig. 
15) the level at which secondary binding takes place (above rb = 0.05, 
Fig. 9a), any differences seen between the mechanisms of RNA synthesis 
(e.g. RS to OP transformation) by group I and group II drugs cannot be 
attributed to secondary binding. 
A possible cause for the additional step of inhibition of RS to OP 
transformation by group I drugs then, is the presence of electrostatic 
interaction between their amino groups and the phosphate backbone of 
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DNA in the intercalated complex. This electrostatic interaction may 
impair the catalytic function of the RNA polymerase by interfering at 
the catalytic site in a manner which inhibits the formation of the first 
phosphodiester bond. The same electrostatic interaction within the 
intercalated complex may also retard the rate of elongation. 
In contrast, group II anthracyclines, which do not carry a posi-
tively charged amino group and are therefore unable to interact electro-
statically with DNA phosphate, apparently interfere only with the for-
mation of I complexes and have no effect on the formation of the first 
phosphodiester bond. 
The results presented in this dissertation suggests that the 
unsubstituted amino group on the primary sugar residue of anthracyclines 
may play an imporant role in determining the mechanism by which anthra-
cyclines inhibit RNA synthesis. Both group I and group II anthracyclines 
inhibit RNA synthesis by interfering with the formation of a specific 
template-RNA polymerase binary complex (I complex). However, in addition 
to inhibiting the formation of the I complex, group I anthracyclines in-
terfere with the transformation of the rapidly starting complex (RS 
complex) to the OP complex, (i.e., a complex containing the first 
phosphodiester bond of the nacent RNA chain) and with the elongation of 
RNA chains. 
CHAPTER V 
SUMMARY 
The in vitro synthesis of RNA catalyzed by E. coli DNA-dependent 
RNA polymerase using T7 DNA as template is inhibited by anthracycline 
analogs. 
The initiation step of RNA synthesis is a multi-step process in-
volving 1) the binding of the enzyme molecules to the non-specific bind-
ing sites on the template, 2) the binding of the enzyme molecules to 
major promoters to form I complex, 3) the melting of the double-stranded 
DNA at enzyme binding site to form RS complex and 4) the formation of the 
first phosphodiester bond. 
Anthracyclines apparently inhibit RNA synthesis by intercalating 
into DNA double helix and interfering with template function. In the pre-
sent study two groups of anthracyclines which differ in the substituents 
at C-10 of the aglycone and the amino group of the primary sugar moiety, 
were examined to determine their relative effectiveness in binding to DNA 
and in inhibiting the synthesis of RNA. 
When identical amounts of anthracycline from each group are added 
to DNA, group II anthracyclines (which carry a carbomethoxy group at C-10 
and a substituted amino group on the sugar moiety) inhibit overall RNA 
synthesis to a greater extent than group I drugs. This higher inhibitory 
effectiveness of group II anthracyclines towards overall RNA synthesis is 
the result of their better binding for DNA. However, when comparisons are 
made with the same number of molecules from each group of anthracyclines 
bound to DNA, group I anthracyclines show a higher effectiveness as inhi-
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bitors of RNA synthesis. This enhanced inhibitor activity is attributed 
to a distinctive feature in the mechanism by which group I anthracyclines 
inhibit RNA synthesis. Group I anthracyclines reduce not only the number 
of I complexes that can be formed, but also the rate of transformation of 
these complexes from RS to OP form as well as the rate of RNA chain elon-
gation. In contrast, group II anthracyclines act only by limiting the 
number of I complexes. 
In conclusion, it appears that group I anthracyclines inhibit the 
formation of I complex through intercalation and the rate of RS to OP 
transformation and RNA chain elongation through electrostatic interactions 
within the intercalated complex, thus acting as multiple inhibitors. In 
contrast, group II anthracyclines, which carry substituted amino groups, 
and are thus unable to form similar ionic interactions, inhibit, as a 
result of intercalation, only the formation of I complex. 
BIBLIOGRAPHY 
Aktipis, S., and N. Panayotatos. (1982) A kinetic study on the 
mechanism of inhibition of RNA synthesis catalyzed by DNA-
dependent RNA polymerase. Differences in inhibition by Ethidium 
Bromide, 3,8-diamino-6-ethylphenanthridinium bromide and actino-
mycin D. Biochim, Biophys. Acta 655:278. 
Aktipis, s., and N. Panayotatos. 
thridines on the synthesis 
ribonucleic acid-dependent 
Pharmacal. 13:706. 
(1977) The inhibitory effect of phenan-
of ribonucleic acid catalyzed by deoxy-
ribonucleic acid polymerase. Mol. 
Anderson, W., M. Gottesman, and I. Pastan. (1974) Studies with cyclic 
AMP receptor and stimulation of in vitro transcription of the gal 
operon. J. Biol. Chern. 249:3592. 
Angiuli, R., E. Foresti, L. Riva Di Sanseverino, N. Issacs, 0. Kennard, 
W. Motherwell, D. Wampler, and F. Arcamone. (1971) Structure of 
daunomycin: X-ray analysis of daunomycin solvate. Nature New 
Biol. 234:78. 
Arcamone, F., G. Franceschi, P. Orezzi, G. Cassinelli, w. Barbier, and 
R. Mondelli. (1964a) Daunomycin. I. The structure of daunomy-
cinone. J. Am. Chern. Soc. 86:5334. 
Arcamone, F., G. Franceschi, P. Orezzi, G. Cassinnelli, and R. Mondelli. 
(1964b) Daunomycin. II. The structure of daunosamine. J. Am. Chern. 
Soc. 86:5335. 
Arcomone, F., G. Cassinelli, G. Fantini, A. Grein, P. Orezzi, C. Pol, and 
C. Spalla. (1969a) Adriamycin, 14-hydroxydaunomycin, a new anti-
tumor antibiotic from s. peucetius var, casesius. Biotechnol. 
Bioeng. ~:1101. 
Arcamone, F., G. Franceschi, P. Orezzi, s. Pence, and R. Modelli. (1968) 
The structure of daunomycin. Tetrahedron Letters 3349. 
Arcamone, F., G. Franceschi, S. Pence, and A. Selva. (1969b). Adriamy-
cin (14-hydroxydaunomycin), a novel antitumore antibiotic. 
Tetrahedron Letters. 13:1003. 
Arcamone, F., L. Bernardi, P. Giardino, B. Patelli, A. DiMarco, 
A. Gasazza, G. Pratesi, and P. Reggiane. (1976) Synthesis and 
antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-
diepidaunorubicin, and their ~ anomers. Cancer Tret. Rep. 60:829. 
159 
160 
Arcamone, F., S. Penco, A. Vigevani. (1975) Synthesis and antitumor 
properties of new glycosides of daunomycinone and adriamycinone. 
J. Med. Chern. 18:703. 
Bachur, N.R., M. Gee (1971) Daunorubicin metabolism by rat tissue 
preparations. J. Pharmacal. Exp. Ther. 177:567. 
Bachur, N.R., and M. Gee (1972) Oxygen sensitive reductive cleavage of 
daunorubicin and adriamycin. Fed. Proc. ~:835. 
Bachur, N.R., R. Hildebrand, and R. Jaenke. (1974) Adriamycin and 
daunorubicin disposition in the rabbit. J. Pharmacal. Exp. 
Ther. 191:331. 
Barthelemy-Clavey, V., C. Molinier, G. Aubel-Sadron, and R. Maral. 
(1976) Daunorubicin inhibition of DNA-dependent RNA polymerase 
from Ehrlich ascites tumor cells. Eur. J. Biochem. 69:23. 
Bautz, E., and F. Bautz. (1971) Studies on the function of the RNA 
polymerase sigma factor in site selection. Cold Spring Harbor 
Symp. Quant. Biol. ~:227. 
Beabealashvilly, R., V. Ivanov, L. Minchenkova, and L. Savotchkina. 
(1972) RNA polymerase-DNA complexes. I. The study of the con-
formation of nucleic acids at the growing point of RNA in an 
RNA polymerase-DNA system. Biochim. Biophys. Acta. 259:35. 
Becker, Y. (1972) Theory of the organization of the mammlian cell and 
viral DNA genomes and the mechanism of carcinogenesis. J. Theor. 
Biol. 34:47. 
Berg, D., K. Barrett, and M. Chamberlin. (1971) Purification of two 
forms of E. coli RNA polymerase and sigma components. In Methods 
of Enzymology (eds. S. Colowick and N. Kapland). 21:506. 
Academic Press, New York. 
Bernard, J., R. Paul, M. Boiron, C. Jacouillat, and R. Maral. (1969) 
Rubidomycin. Springer, Berlin-Heidelberg-New York. 
Bhuyan, B.K., and e.G. Smith. (1965) Differential interaction of nogala-
mycin with DNA of varying base composition. Proc. Natl. Acad. 
Sci. USA. 54:566. 
Bonadonna, G., and s. Monfardini. (1969) Cardiac toxicity of daunomycin. 
Lancet. 1:837. 
Bonadonna, G., s. Monfardini, M. DeLena, F. Fossati-Bellani, and G. 
Beretta. (1970) Phase I and preliminary phase II evaluation of 
adriamycin (NSC-123,127). Cancer Res. 30:2572. 
161 
Bram, s. (197la) Secondary structure of DNA depends on base composition 
Nature New Biol. 232:174. 
Bram, s. (197lb) Polynucleotide polymorphism in solution. Nature New 
Biol. 233:161. 
Brown, J.R. (1978) Adriamycin and Related Anthracycline antibiotics. 
Prog. Med. Chern. _!2: 125. 
Burgess, R.R. (1971) RNA polymerase. Ann. Rev. Biochem. 40:711. 
Burgess, R.R. (1969) Separation and characterization of the subunits of 
ribonucleic acid polymerase. J. Biol. Chern. 244:6168. 
Calendi, E., R. Dettori, and M. Neri. (1966) Filamentous sex-specific 
bacteriophage of E. coli Kl2. IV. Studies on physico-chemical 
characteristics of bacteriophage Ec9. Giorn. Microbial. 14:227. 
Calendi, E., A. DiMarco, M. Reggiani, B. Scarpinato, and L. Valentini. 
(1965) On physico-chemical interactions between daunomycin and 
nucleic acids. Biochim. Biophys. Acta. 103:25. 
Chamberlin, M., and J. Ring. (1972) Studies of the binding of E. coli 
RNA polymerase to DNA. V. T7 RNA chain initiation by enzyme-DNA 
complexes. J. Mol. Biol. 70:221. 
Chamberlin, M. (1974a) The selectivity of transcription. Ann. Rev. 
Biochem. 43:721. 
Chamberlin, M. (1974b) Bacteria DNA-dependent RNA polymerase. In The 
Enzymes (ed. P.D. Boyer), vol. 10, p.333. Academic Press, New York. 
Chamberlin, M. (1976) Interaction of RNA polymerase with the DNA tem-
plate. In RNA Polymerase (ed. M. Chamberlin), p. 159. Cold 
Spring Harbor Laboratory. 
Chambon, P. (1975) Eukaryotic nuclear RNA polymerases. Ann. Rev. 
Biochem. 44:613. 
Chen, B., B. de Crombrugghe, W. Anderson, M. Gottesman, and I. Pastan. 
(1971) On the mechanism of action of lac repressor. Nature New 
Biol. 233:67. 
Cohen, A., E.M. Harley, and K.R. Rees. 
daunomycin. Nature. 222:36. 
(1969) Antiviral effect of 
Cradock, J.C., .H.J. Egorin, and N.R. Bachur. (1973) Daunorubicin 
biliary excretion and metabolism in the rat. Arch. Int. 
Pharmacodyn. Ther. 302:48. 
Crook, L.E., K.R. Rees, and A. Cohen. (1972) Effect of daunomycin on 
Hela cell nucleic acid synthesis. Biochem. Pharmacol. 21:281. 
Crooke, s., V. DuVernay, L. Galvan, and A. 
Structure-activity relationships of 
effect on macromolecular synthesis. 
Prestayko. (1977) 
anthracyclines relative to 
Mol. Pharmacol. 14:290. 
162 
Dano, K., S. Frederiksen, and P. Hellung-Larsen. (1972) Inhibition of 
DNA and RNA synthesis by daunorubicin in sensitive and resistant 
Ehrlich ascites tumor cells in vitro. Cancer Res. 32:1307. 
Dausse, J., A. Sentenac and P. Fromageot. (1972) Interaction of RNA 
polymerase from E. coli with DNA: Selection sites on T7 DNA. 
Eur. J. Biochem. 26:43. 
Dausse, J., A. Sentenac and P. Fromageot. (1976) Interaction of RNA 
polymerase from E. coli with DNA. Effect of temperature and 
ionic strength on selection of T7 DNA early promoters. Eur. J. 
Biochem. 65:387. 
Davis, R., and R. Hyman~ (1971) Physical locations of the in vitro RNA 
i~itiation site and termination sites on T7 DNA. Cold spring 
Harbor Symp. Quant. Biol. E:269. --
Di Fronzo, G., and R.A. Gambetta. (197la) "In vivo" studies on the dis-
tribution of 3H-daunomycin in tumors and in different tissues of 
the mouse. Eur. J. Clin. Biol. Res. 16:50. 
Di Fronzo, G., R.A. Gambetta, and L. Lenza. (197lb) Distribution and 
metabolism of adriamycin in mice. Comparison with daunomycin. 
Eur. J. Clin. Biol. Res. 16:972. 
DiMarco, A., Gaetani, M., P. Orezzi, B. Scarpinato, R. Silvestrini, 
M. Soldati, T. Dasdia, and L. Valentini. (1964a) Daunomycin, 
a new antibiotic of the rhodomycin group. Nature. 201:706. 
DiMarco, A., M. Gaetani, L. Dorigotti, M. Soldati, and o. Bellini. 
(1964b) Daunomycin: A new antibiotic with antitumor activity. 
Cancer Chemotherapy Rep. 38:31. 
Di Marco, A. (1967) Daunomycin and related antibiotics. Antibiotics, 
vol. I, p. 190. (eds. Gottlieb and Shaw). Springer, Berlin-
Heidelberg-New York. 
Di, Marco, A. F. Arcamone, F. Zunino. (1975) Daunomycin and adriamycin 
and structural analogues: Biological activity and mechanism of 
action. Antibiotics, vol. III, p. 101. (eds. Corcoran and Hahn). 
Springer, New York. 
163 
DiMarco, A., M. Terni, R. Silvestrini, B. Scarpinato, E. Biagioli, 
and A. Antonelli. (1968) Effect of daunomycin on Herpes Virus 
hominis in human cell. Giorn. Microbial. 16:25. 
Di Marco, A. (1970) Daunomycin. Milano: Minerva Medica. 
DiMarco, A., M. Gaetani, and B. Scarpinato. (1969) Adriamycin 
(NSC-123, 127): A new antibiotic with antitumor activity. Cancer 
Chemotherapy Rep. 2l:33. 
Di Marco, A. (197la) Adriamycin. The therapeutic activity on experi-
mental tumors. International Symposium on Adriamycin, Milano. 
DiMarco, A., R. Silvestrini, s. DiMarco, and T. Dasdia. 
Inhibition effect of the new cytotoxic antibiotic 
nucleic acids and mitotic activity of Hela cells. 
27:545. 
(1965) 
daunomycin on 
J. Cell Biol. 
Dimarco, A., F. Zunino, R. Silvestrini, c. Gambarucci, and R. Gambetta. 
(197lb) Interaction of some daunomycin derivatives with DNA and 
their biological activity. Biochem. Pharmacal. 20:1323. 
DiMarco, A., F. Zunino, P. Orezzi, and R. Gambetta. (1972) Interaction 
of daunomycin with nucleic acids. Effect of photo-irridation of 
the complex. Experientia. 28:327. 
DiMarco, A., A. Casazza, T. Dasdia, A. Necco, G. Pratesi, P. Rivolta, 
A. Velcich, A. Zaccara, and F. Zunino. (1977) Changes of activi-
ty of daunorubicin, adriamycin and stereoisomers following the 
introduction or removal of hydroxyl groups in the amino sugar 
moiety. Chern. Biol. Inter. 19:291. 
DiMarco, A., M. Casazza, F. Giuliani, G. Pratesi, F. Arcamone, L. 
Bernardi, G. Franchi, P. Giardino, B. Patelli, and s. Penco. 
(1978) Synthesis and antitumor activity of 4-demethoxyardria-
mycin and 4-demethoxy-4-epiadriamycin. Cancer Treat. Rep. ~:375. 
Drummond, D., N. Pritchard, V. Simpson-Gildemeister and A. Peacock. 
(1966) Interaction of aminoacridines with deoxyribonucleic acid: 
Viscosity of the complexes. Biopolymers. ±:971. 
Dunn, J., and F. Studier. (1973) T7 early RNAs are generated by site 
specific cleavages. Proc. Nat. Acad. Sci. 70:1559. 
DuVernay, V., J. Pachter, and S. Crooke. (1980) Molecular pharmacologi-
cal differences between carminomycin and its analog, carminomycin-
11-methyl ether, and adriamycin. Cancer Res. 40:387. 
DuVernay, V., J. Pachter, and S. Crooke. (1979a) DNA binding studies on 
several new anthracycline antitumor antibiotics. II. The impor-
tance of the carbomethoxy-group at position-10 of the class II 
anthracycline molecules. Mol. Pharmacal. 16:623. 
DuVernay, V., J. Pachter, and s. Crooke. (1979b) Deoxyribonucleic 
acid binding studies on several new anthracyclines antitumor 
antibiotics. Sequence preference and structure-activity rela-
tionships of marcellomycin and its analogues as compared to 
adriamycin. Biochem. 18:4024. 
164 
Evans, L., D. Linstead, P. Rhodes, D. Wilkie. (1973) Inhibition of RNA 
synthesis in mitochondria by daunomycin. Biochim. Biophys. 
Acta. 312:323. 
Fukuda, R., and A. Ishihama. (1974) Subunits of RNA polymerase in 
function and structure. v. Maturation in vivo of core enzyme 
from E. coli. J. Mol. Biol. 87:523. 
Gabby, E., D. Grier, R. Fingerle, R. Reimer, R. Levy, S. Pearce. 
and w. Wilson. (1976) Interaction specificity of the anthracy-
clines with deoxyribonucleic acid. Biochem. 15:2062. 
Golomb, M., and M. Chamberlin. (1974a) A preliminary map of the major 
transcription units read by T7 RNA polymerase on the T7 and T3 
bacteriophage chromosomes. Proc. Nat. Acad. Sci. 71:760. 
Golomb, M. (1974b) In vitro transcription by T7 RNA polymerase. Ph.D. 
dissertation. University of California, Berkeley. 
Goodman, M.F., M.J. Bessman, and N.R. Bachur. (1974) Adriamycin and 
daunomycin inhibition of mutant T4 DNA polymerase. Proc. Nat. 
Acad. Sci. USA. 71:1193. 
Goodman, M.F., and G. Lee. (1977) Adriamycin interactions with T4 DNA 
polymerase. Two modes of template-mediated inhibition. J. Biol. 
Chern. 252:2670. 
Heil, A., and W. Zillig. (1970) Recombination of bacterial DNA-dependent 
RNA polymerase from isolate subunits as a tool for the eluciadation 
of the role of the subunits in transcription. FEES Lett. 11:165. 
Heyden, B.C., c. Nusslein, and H. Schaller. (1972) Single RNA polymerase 
binding site isolated. Nature New Biol. 240:9. 
Hinkle, D.C., and M.J. Chamberlin. (1972a) Studies of the binding of E. 
coli RNA polymerase to DNA. I. The role of sigma subunit in site 
selection. J. Mol. Biol. 70:157. 
Hinkle, D.C., and M.J. Chamberlin. (1972b) Studies of the binding of E. 
coli RNA polymerase to DNA. II. The kinetics of binding reaction. 
J. Mol. Biol. 70:187. 
Hinkle, D.C., J. Ring and M.J. Chamberlin. (1972c) Studies of the bind-
ing of E. coli RNA polymerase to DNA. III. Tight binding of RNA 
polymerase holoenzyme to single-strand breaks in T7 DNA. J. Mol. 
Biol. 70:197. 
Hinkle, D.C., W.F. Mangel, and M.J. Chamberlin. 
binding of E. coli RNA polymerase to DNA. 
picin on binding and RNA chain initiation. 
165 
(1972d) Studies of the 
IV. The effect of rifam-
J. Mol. Biol. 70:209. 
Jones, o., and P. Berg. (1966) Studies on the binding of RNA polymerase 
to polynucleotides. ~· Mol. Biol. ~:199. 
Kersten, w., H. Kersten, and W. Szybalski. 
perties of complexes between DNA and 
synthesis. Biochem. 5:236. 
(1966) Physico-chemical pro-
antibiotics which affect RNA 
Kersten, w. (1971) Inhibition of RNA synthesis by quinone antibiotics. 
Progress in molecular and subcellular biology. 2:48. 
Kim, K.H., A.S. Gelbard, B. Djordjevic, S.H. Kim, and A.G. Perez. (1968) 
Action of daunomycin on the nucleic acid metabolism and viability 
of Hela cells. Cancer Res. 28:2437. 
Krakow, J.S., and K. von der Helm. (1971) Azotobacter RNA polymerase 
transitions and the realease of sigma. Cold Spring Harbor Symp. 
Quant. Biol. 35:73. 
Li, H., and D. Crothers. (1969) Relaxation studies of the proflavine-DNA 
complex: the kinetics of an intercalation reaction. ~- Mol. Biol. 
39:461. 
Lill, H.R., and G.R. Hartmann. (1975b) Digestion with matrix-bound pro-
teases as a possible probe for the topography of the DNA-dependent 
RNA polymerase from E. coli. Eur. J. Biochem. 54:45. 
Lill, U.I., E.M. Behrendt, and G.R. Hartmann. (1975a) Hybridization in 
vitro of subunits of the DNA-dependent RNA polymerase from E. coli 
and Micrococus luteus. Eur. J. Biochem. 52:411. 
Mangel, W., and M.J. Chamberlin. (1974a) Studies of ribonucleic acid 
chain initiation by E. coli ribonucleic acid polymerase bound to 
T7 deoxyribonucleic acid. III. The effect of temperature on ribo-
nucleic acid chain initiation and on the conformation of binary 
complexes. J. Biol. Chern. 249:3007. 
Mangel, W., and M. Chamberlin. (1974b) Studies of ribonucleic acid chain 
initiation by E. coli ribonucleic acid polymerase bound to T7 
deoxyribonucleic acid. II. The effect of alterations in ionic 
strength on chain initiation and on the conformation of binary 
complexes. J. Biol. Cbem. 249:3002. 
Mangel, W., and M. Chamberlin. (1974c) Studies of ribonucleic acid chain 
initiation by E. coli ribonucleic acid polymerase bound to T7 de-
oxyribonucleic acid. I. An assay for the rate of andextent of ribo-
nucleic acid chain initiation. J. Biol. Chern. 249:2995. 
166 
Meriwether, w., and N. Bachur. (1972) Inihition of DNA and RNA metabolism 
by daunorubicin and adriamycin in Ll210 mouse leukemia. Cancer 
Res. 32:1137. 
Meilhac, M., z. Tysper, and P. Chambon. (1972) Animal DNA-dependent RNA 
polymerase. 4. Studies on inhibition by rifamycin derivatives. 
Eur. J. Biochem. 28:291. 
Millette, R. c. Trotten, 0. Herrlich, and M. Schweiger. (1970) In vitro 
synthesis, termination, and release of active messenger RNA. Cold 
Spring Harbor Symp. Quant. Biol. ~:135. 
Minkley, E., and D. Pribnow. (1973) Transcription of the early region 
of bacteriophage T7: Selective initiation with dinucleotides. 
J. Mol. Biol. 77:255. 
Mizuno, N.S., B. Zakis, and R.W. Decker. (1975) Binding of daunomycin to 
DNA and inhibition of RNA and DNA synthesis. Cancer Res. 25:1542. 
Momparler, M., M. Karon, S. Siegel, and F. Avila. (1976) Effect of adria-
mycin on DNA, RNA, and protein synthesis in cell-free systems and 
intact cells. Cancer Res. 36:2891. 
Murphree, S.A., L.S. Cunningham, K.M. Hwang, and A.C. Sartorelli. (1976) 
Effects of adriamycin on surface properties of sarcoma 180 ascites 
cells. Biochem. Pharmacal. 25:1227. 
Nakanishi, s., s. Adhya, M. Gottesman, and I. Pastan. (1974) Activation 
of transcription at specific promoters by glycerol. ~· Biol. Chern. 
249:4050. 
Neidle, S. (1977) A hypothesis concerning possible new derivatives of 
daunomycin and adriamycin with enhanced DNA-binding properties. 
Cancer Treat. Rep. 61:928. 
Nettleton, D., Jr., W. Bradner, J. Bush, A. Coon, J. Moseley, R. Myllymaki, 
F. O'Herron, R. Schreiber, and A. Vulcano. (1977) New antitumor 
antibiotics: musettamycin and marcellomycin from bohemic acid 
complex. J. Antibiotics 30:525. 
Oki, T., T. Matsuzawa, A. Yoshimato, K. Numata, I. Kitamura, S. Hori, A. 
Takamatsu, H. Umezama, M. Ishizuka, H. Haganawa, H. Suda, M. 
Hamada, and T. Takeuchi. (1975) New antitumor antibiotics, 
aclacinomycin A and B. J. Antibiotics. 28:830. 
Ollis, W.D., and I.O. Sutherland. (1961) Chemistry of natural phenolic 
compounds (ed. W.D. Ollis), p.212, Oxford: Pergmon. 
Palm, P., A. Heil, D. Boyd, B. Grampp, and W. Zillig. (1975) The recon-
sitution of E. coli DNA-dependent RNA polymerase from its isolated 
subunits. Eur. J. Biochem. 53:283. 
167 
Parisi, B., and A. Soller. (1964) Studies on the antiphage activity of 
daunomycin. Giorn. Mircobiol. 12:183. 
Peacocke, A.R., and J.N. Skerrett. (1956) The interaction of amino-
acridines with nucleic acids. Trans. Faraday. Soc. 56:261. 
Pettijohn, D., and T. Kamiya. (1967) Interaction of RNA polymerase with 
polymer DNA. J. Mol. Biol. 29:275. 
Pigram, W.J., W. Fuller, and L.D. Hamilton. (1972) Sterochemistry of 
intercalation: Interaction of daunomycin with DNA. Nature New 
Biol. 235:17. 
Plumbridge, T.W., and J.R. Brown. (1977) Spectrophotometric and fluo-
resence polarization studies of the binding of ethidium daunomycin 
and mepacrine to DNA and to poly (I•C). Biochim. Biophys. Acta. 
479:441. 
Plumbridge, T.W., and J.R. Brown. (1979) The interaction of adriamycin 
and adriamycin analogues with nucleic acids in the B and A con-
formations. Biochim. Biophys. Acta. 563:181. 
Plumbridge, T.W., and J.R. Brown. (1978) studies on the mode of inter-
action of 4'-epiadriamycin and 4-demethoxydaunomycin with DNA. 
Biochem. Pharmacol. 27:1881. 
Pribnow, D., (1975) Necleotide sequence of an RNA polymerase binding 
site at an early T7 promoter. Proc. Nat. Acad. Sci. 72:784. 
Rabussay, D., and w. Zillig. (1969) A rifampicin resistant RNA poly-
merase from E. coli altered in the ~-subunit. FEBS Letts. 5:104. 
Record, M.T., Jr., P. deHaseth, and T. Lohman. (1976) Ion effects on 
protein nucleic acid interactions. J. Mol. Biol. 107:145. 
Rexer, B., v. Srinivasan, and w. Zillig. (1975) Regulation of trans-
cription during sporulation of Bacillus cireus T. Eur. J. Biochem. 
53:271. 
Richardson, c.c. (1966) The 5'-terminal nucleotides of T7 bacteriophage 
deoxyribonucleic acid. J. Mol. Biol. 15:49. 
Richardson, J. (1975) Initiation of transcription by E. coli RNA poly-
merase from supercoiled and non-supercoiled bacteriophage pm2 DNA. 
J. Mol. Biol. 91:477. 
Rovozzo, G., and C. Burke. (1973) A manual of basic virological techni-
ques. p.86. Prentice-Hall, Inc. Englewood Cliffs, New Jersey. 
Rusconi, A., and E. Calendi. (1966) Action of daunomycin on nucleic acid 
metabolism. Biochim. Biophys. Acta. 119:413. 
168 
Rich, A., G. Quigley, and A. H-J Wang. (1981) DNA: Right-handed and 
left-handed helical conformation. In Biomolecular Steredynamics, 
(ed. R. Sarma), val. 1, p.35. Adenine press. 
Rusconi, A., and A. DiMarco. (1969) Inhibition of nucleic acid synthesis 
by daunomycin and its relationship to the uptake of the drug in 
Hela cells. Cancer Res. 29:1509. 
Rusconi, A. (1964) Action of daunomycin on nucleic acid synthesis in 
Hepatoma ascites cells incubated in vitro. Tumori. 50:261. 
Sandberg, J.S., F.L. Howsden, A. DiMarco and A. Goldin. (1970) Com-
parison of the antileukemic effect in mice of adriamycin (NSC-
123, 127) with daunomycin (NSC-82151). Cancer Chemotherapy 
Rept. 54:1. 
Saucier, J., and J. Wang. (1972) Angular alteration of the DNA helix by 
E. coli RNA polymerase. Nature New Biol. 239:167. 
Scatchard, G. (1949) The attractions of proteins for small molecules 
and ions. Ann. N.Y. Acad. Sci. 51:660. 
Schellinx, J.A., P. Dijkwel, and W. Friedrich. (1979) Inhibition of DNA 
synthesis in mammalian cells by daunomycin: Preferential inhibi-
tion of replicon initiation at low concentrations. Eur. J. 
Biochem. 102:409; 
Seeburg, P., and H. Schaller. (1975) Mapping and characterization of 
promoters in bacteriophages fd, fl and Ml3. J. Mole. biol. 92:261. 
Sethi, v.s. (1971) Structure and function of DNA-dependent RNA polymerase. 
Prog. Biophys. Mol. Biol. 23:67. 
Siddhikol, C., J.W. Erbstoeszer, and B. Weisblum. 
of streptolydigin. J. Bact. 99:151. 
(1969) Mode of action 
Silvestrini, R., A. DiMarco, and T. Dasdia. (1970) Interference of 
daunomycin with metabolic events of the cell cycle in synchronized 
cultures of rat fibroblasts. Cancer Res. 30:966. 
--- --
Silvestrini, R., and M. Gaetani. (1963) The action of daunomycin on the 
metabolism of nucleic acids of Ehrlich ascites tumor cells. 
Tumori, 49:389. 
Simard, R. (1967) The binding of actinomycin D- 3H to heterochromatin as 
studied by quantitative high resolution radioautography. ~· Cell. 
Biol. 35:716. 
Sippel, A., and G. Hartmann. (1968) Mode of action of rifampicin on the 
RNA polymerase reaction. Biochim. Biophys. Acta. 157:218. 
169 
Stahl, s., and M. Chamberlin. (1977) An expanded transcriptional map of 
T7 bacteriophage. Reading of minor T7 promoter sites in vitro by 
E. coli RNA polymerase. J. Mol. Biol. 112:577. 
Stetter, K.O., and W. Zillig. (1974) Transcription in Tactobacillaceae. 
DNA-dependent RNA polymerase from Lactobacillus curvatus. Eur. 
J. Biochem. 48:527. 
Surzycki, s., J. Surzycki, W. Delorbe, and G. Gussin. (1976) In vitro 
transcription of adenovirus DNA. II. Quantitation and localization 
of promoters for E. coli RNA polymerase. Mol. Gen. Genet. 143:177. 
Takanashi, s., and N.R. Bachur. (1975) Daunorubicin metabolites in 
human urine. J. Pharmaco. Exp. Ther. 195:41. 
Tanaka, M., and s. Yoshida. (1980) Mechanism of the inhibition of Calf 
thymus DNA polymerases~and ~by daunomycin and adriamycin. J. 
Biochem. 87:911. 
Thomas, c., and J. Abelson. (1966) The isolation and characterization 
of DNA from bacteriophage. In Procedures in Nucleic Acid Research 
(eds. G. Cantoni and D. Davis) vol. 1, p. 553, Harper and Row, 
New York. 
Travers, A., and R.R. Burgess. (1969) Cyclic re-use of the RNA polymerase 
sigma factor. Nature. 222:537. 
von Hippel, P., and J. McGhee. (1972) DNA-protein interactions. Ann. 
Rev. Biochem. 41:231. 
von Hippel, P., A. Revzin, C. Gross, and A. Wang. (1975) Interaction of 
lac repressor with non-specific DNA binding sites. In Protein-
ligand Interactions (ed. H. Sund and G. Blauer), p. 270. Walter 
de Gruyter, Berlin. 
Verini, M.A., A.M. Casazza, A. Fioretti, F. Rodenghi, and M. Ghione. 
(1968) Photodynamic action of daunomycin. II. Effect on animal 
viruses. Giorn. Microbial. 16:55. 
Walter, G., W. Zillig, P. Palm, and E. Fuchs. (1967) Initiation of DNA-
dependent RNA synthesis and the effect of heparin on RNA poly-
merase. Eur. J. Biochem. 3:194. 
Wang, J., M. Barkley and S. Bourgeois. (1974) Measurements of unwinding 
of lac operator by repressor. Nature. 251: 247. 
Ward, D., E. Reich, and I. Goldberg. (1965) Base specificity in the 
interaction of polynucleotides with antibiotic drugs. Science. 
149:1259. 
170 
Wehrli, W., F. Knusel, and M. Staehelin. (1968) Action of rifampicin on 
RNA synthesis. Proc. Nat. Acad. Sci. USA. 61:667. 
Windell, c., and J. Tata. (1966) Studies on the simulation by ammonium 
sulphate of the DNA-dependent RNA polymerase of isolated rat liver 
nuclei. Biochim, Biophys. Acta. 123:478. 
Yamamoto, K., B. Alberts, R. Benzinger, L. Lawhorne, and G. Treiber. 
(1970) Rapid bacteriophage sedimentation in the presence of poly-
ethylene glycol and its application to large-scale virus purifica-
tion. Virology. 40:734. 
Yarbrough, L., and J. Hurwitz. (1974) The isolation of subunits of de-
oxyribonucleic acid-dependent ribonucleic acid polymerase of E. 
coli. J. Biol. Chern. 249:5400. 
Yesair, D.W., M.A. Asbell, R. Bruni, F. Bullock, and E. Schwartzbach. 
(1971) Pharmacokinetics and metabolism of adriamycin and daunomy-
cin. International symposium on adriamycin, Milano. 
Yunis, J., and W. Yasmineh. (1971) Heterochromatin, satellite DNA, and 
cell function. Structural DNA of eukaryotes may support and 
protect genes and aid in speciation. Science. 174:1200. 
Zeleznick, L.D., and C.M. Weeney. (1967) Inhibition of deoxyribonuclease 
action by nogalamycin and U-12241 by their interaction with DNA. 
Arch. Biochim. Biophys. 120:292. 
Zillig, W., P. Palm, and A. Heil. (1976) Function and reassembly of sub-
units of DNA-dependent RNA polymerase. In RNA Polymerase (ed. 
Chamberlin), p. 101. Cold Spring Harbor Laboratory. 
Zillig, W., K. Zechel, D. Rabussay, M. Schachner, V. Sethi, P. Palm, 
A. Heil, and W. Seifert. (1971) On the role of different sub-
units of DNA-dependent RNA polymerase from E. coli in the 
transcription process. Cold Spring Harbor Symp. Quant. Biol. 
35:47. 
Zunino, F., R. Gambetta, A. A. DiMarco, and A. Zaccara. (1972) Inter-
action of daunomycin and its derivatives with DNA. Biochim. 
Biophys. Acta. 277:489. 
Zunino, F. 
DNA. 
(1971) Studies on the mode of interaction of daunomycin with 
FEBS Letts. 18:249. 
Zunino, F., R. Gambetta, A. DiMarco, A. Velcich, A. Zaccara, F. Quad-
rifoglio, and V. Crescenzi. (1977) The interaction of adriamycin 
and its e anomer with DNA. Biochim. Biophys. Acta. 476:38. 
Zunino, F., A. DiMarco, A. Zaccara, and G. Luoni. (1974) The inhibition 
of RNA polymerase by daunomycin. Chern. Biol Int. 9:25. 
171 
Zunino, F., R. Gambetta, A. DiMarco, G. Luoni, and A. Zaccara. (1976) 
Effects of the stereochemical configuration on the interaction 
of some daunomycin derivatives with DNA. Biochem. Biophys. Res. 
Comm. 69:744. 
Zunino, F., A. DiMarco, A. Zaccara, and R. Gambetta. (1980) The inter-
action of daunorubicin and doxorubicin with DNA and chromatin. 
Biochim. Biophys. Acta. 607:206. 
APPROVAL SHEET 
The dissertation submitted by Daniel Meng has been approved by the 
following committee: 
Stelios Aktipis, Ph.D., Director 
Professor, Biochemistry and Biophysics 
Loyola Stritch School of Medicine 
Allen Frankfater, Ph.D. 
Associate Professor, Biochemistry and Biophysics 
Loyola Stritch School of Medicine 
Alexander Friedman, Ph.D. 
Professor, Pharmacology 
Loyola Stritch School of Medicine 
Eugene Major, Ph.D. 
Infectious Disease Branch 
National Institute of Neurological Communicative 
Disorders and Stroke (NINCDS) 
National Institute of Health 
Richard Schultz, Ph.D. 
Associate Professor, Biochemistry and Biophysics 
Loyola Stritch School of Medicine 
The final copies have been examined by the director of the dissertation 
and the signature which appears below verifies the fact that any 
necessary changes have been incorporated and that the dissertation 
is now given final approval by the Committee with reference to content 
and form. 
The dissertation is therefore accepted in partial fulfillment of the 
ewquirements for the degree of Doctor of Philosophy. 
Date 
~/1~ t1K! ~ '~ 
Director's Si~ 
172 
